Safe harbor loci

JP2023547887A5Pending Publication Date: 2024-11-05ARSENAL BIOSCIENCES INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2023525019
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-04-23
Filing Date
2021-10-26
Publication Date
2024-11-05

AI Technical Summary

Technical Problem

Current cancer treatments, including immunotherapies, face challenges such as low knock-in efficiency, insertional carcinogenesis, unstable transgene expression, and adverse side effects, particularly in treating blood and bone marrow cancers like multiple myeloma, leukemia, and lymphoma.

Method used

Identification and utilization of safe harbor loci within the genome for high-efficiency knock-in and stable expression of transgenes in engineered T cells, using specific integration sites like chr10:33130000~33140000 and GS94, GS102, to enhance cancer immunotherapy.

Benefits of technology

The method provides high knock-in efficiency and stable transgene expression in T cells, reducing adverse effects and improving therapeutic efficacy for cancer treatment.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000000_0001_ABST
    Figure 00000000_0001_ABST
  • Figure 00000000_0000_ABST
    Figure 00000000_0000_ABST
Patent Text Reader

Abstract

Provided herein are safe harbor loci, as well as methods for identifying and using safe harbor loci that exhibit high knock-in efficiency and allow for increased stable expression of transgenes. TIFF2023547887000137.tif40170
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] Cross-reference of related applications This application claims priority and interest to U.S. Provisional Patent Application No. 63 / 179,143 filed on 23 April 2021, U.S. Provisional Patent Application No. 63 / 141,926 filed on 26 January 2021, and U.S. Provisional Patent Application No. 63 / 105,834 filed on 26 October 2020, the entire contents of which are incorporated herein by reference for all purposes.

[0002] Sequence List This application includes a sequence listing filed via EFS-Web, which is incorporated herein by reference in its entirety. The ASCII copy thereof was created on 15 October 2021, named ANB-203WO_SequenceListing, and is 623,177 bytes in size. [Background technology]

[0003] Despite substantial research efforts and scientific advancements in cancer therapy, cancer continues to present a significant clinical burden. Hematological and myelomas are among the most frequently diagnosed cancer types (including multiple myeloma, leukemia, and lymphoma). Current treatment options for these cancers are not effective for all patients and / or may have substantial adverse side effects. Other cancer types also remain difficult to treat using existing treatment options. Cancer immunotherapy is a promising solution because it is highly specific and allows for improved treatment efficacy and reduced side effects.

[0004] Genetically engineered immunotherapy is a growing field with promising applications for the treatment of diseases including but not limited to cancer. By modifying coding and / or non-coding genomic regions, researchers are identifying intracellular transgenes and insertion sites that facilitate, for example, enhanced cellular function, cessation of cell growth, induction of cell death, and reduction of tumor size / volume. The identification of safe harbor sites (SHSs) has improved the outcomes of genomic engineering therapies. Well-known SHSs include the AAVS1 adeno-associated virus insertion site on chromosome 19, the human homolog of the mouse Rosa26 locus, and the CCR5 chemokine receptor gene (its absence confers HIV resistance). (See, for example, Pellenz et al., 2018, this relevant disclosure is incorporated herein by reference). However, the need for improved guidelines for gene editing therapies and additional SHSs remains to address challenges such as low knock-in (KI) efficiency, insertion carcinogenesis, and instability and / or abnormal expression of transgenes and / or adjacent genes. [Overview of the Initiative]

[0005] This disclosure focuses, in particular, on safe harbor loci that exhibit high knock-in efficiency and stable expression of their transgenes. These safe harbor loci can be used to modify T cells for immunotherapy. These safe harbor loci are useful for treating a variety of diseases, including cancer.

[0006] In one embodiment, the disclosure provides an engineered cell comprising at least one sequence encoding a transgene, wherein at least one sequence is inserted into a safe harbor locus, the safe harbor locus is located in one or more of the sgRNA target loci listed in Table 4, and the expression of at least one sequence encoding the transgene is operably linked to an exogenous promoter. In another embodiment, the disclosure provides an engineered cell comprising at least one sequence encoding a transgene, wherein at least one sequence is inserted into a safe harbor locus, the safe harbor locus is located in one or more of the sgRNA target loci listed in Table 4, and the expression of at least one sequence encoding the transgene is operably linked to an exogenous promoter.

[0007] In some embodiments, the target loci are chr10:33130000~33140000, chr10:72290000~72300000, chr11:128340000~128350000, chr11:65425000~65427000 (NEAT1), chr15:92830000~92840000 , chr16:11220000~11230000, chr2:87460000~87470000, chr3:186510000~186520000, chr3:59450000~59460000, chr8:127980000~128000000, and chr9:7970000~7980000. In some embodiments, the target locus is selected from chr10:72290000~72300000, chr11:128340000~128350000, chr15:92830000~92840000, and chr16:11220000~11230000. In some embodiments, the target locus is chr11:128340000~128350000. In some embodiments, the target locus is chr15:92830000~92840000. In some embodiments, the target locus is a gene selected from APRT, B2M, CAPNS1, CBLB, CD2, CD3E, CD3G, CD5, EDF1, FTL, PTEN, PTPN2, PTPN6, PTPRC, PTPRCAP, RPS23, RTRAF, SERF2, SLC38A1, SMAD2, SOCS1, SRP14, SRSF9, SUB1, TET2, TIGIT, TRAC, and TRIM28.

[0008] In some embodiments, the safe harbor locus is selected from any one of the integration sites in Table 4, which are referred to as GS88, GS89, GS90, GS91, GS92, GS93, GS94, GS95, GS96, GS97, GS98, GS99, GS100, GS101, GS102, GS103, GS104, GS105, GS106, GS107, GS108, GS109, GS110, GS111, GS112, GS113, GS114, GS115, GS116, GS117, GS118, GS119, and GS120. In some embodiments, the safe harbor locus is selected from any one of the integration sites in Table 4, referred to as GS91, GS92, GS93, GS94, GS95, GS96, GS100, GS101, GS102, GS103, GS104, and GS105. In some embodiments, the safe harbor locus is selected from any one of the integration sites in Table 4, referred to as GS103, GS104, and GS105. In some embodiments, the safe harbor locus is selected from any one of the integration sites in Table 4, referred to as GS94, GS95, and GS96. In some embodiments, the safe harbor locus is the GS94 integration site in Table 4. In some embodiments, the safe harbor locus is selected from any one of the integration sites in Table 4, referred to as GS100, GS101, and GS102. In some embodiments, the safe harbor locus is the GS102 integration site in Table 4. In some embodiments, the safe harbor locus is selected from one of the integration sites in Table 4, referred to as GS91, GS92, and GS93.

[0009] In some embodiments, the exogenous promoter is the EF1a promoter. In some embodiments, the manipulated cells are stem cells, human cells, primary cells, hematopoietic cells, adaptive immune cells, innate immune cells, T cells, or T cell precursors. In some embodiments, the transgene encodes a recombinant protein, optionally a therapeutic agent. In some embodiments, the transgene encodes a chimeric antigen receptor (CAR).

[0010] In another embodiment, the present disclosure provides compositions comprising the manipulated cells and pharmaceutical excipients described herein.

[0011] In another embodiment, the present disclosure provides a guide ribonucleic acid (gRNA) for editing cells at a safe harbor locus, wherein the gRNA comprises one of the sgRNA sequences in Table 4.

[0012] In some embodiments, the gRNA comprises one of sequence numbers 1 to 120. In some embodiments, the gRNA comprises one of sequence numbers 91 to 96 and 100 to 105. In some embodiments, the gRNA comprises sequence number 94 or sequence number 102. In some embodiments, the gRNA comprises sequence number 94. In some embodiments, the gRNA comprises sequence number 102. In some embodiments, the cells are stem cells, human cells, primary cells, hematopoietic cells, adaptive immune cells, innate immune cells, T cells, or T cell precursors.

[0013] In another embodiment, the Disclosure provides a method for editing a cell having chromosomal DNA, comprising inserting at least one sequence encoding a transgene into a safe harbor locus of the cell's chromosomal DNA, wherein the safe harbor locus is one or more of the sgRNA target loci listed in Table 4.

[0014] In some embodiments, the target loci are chr10:33130000~33140000, chr10:72290000~72300000, chr11:128340000~128350000, chr11:65425000~65427000 (NEAT1), chr15:92830000~92840000 , chr16:11220000~11230000, chr2:87460000~87470000, chr3:186510000~186520000, chr3:59450000~59460000, chr8:127980000~128000000, and chr9:7970000~7980000. In some embodiments, the target locus is selected from chr10:72290000~72300000, chr11:128340000~128350000, chr15:92830000~92840000, and chr16:11220000~11230000. In some embodiments, the target locus is chr11:128340000~128350000. In some embodiments, the target locus is chr15:92830000~92840000. In some embodiments, the target locus is a gene selected from APRT, B2M, CAPNS1, CBLB, CD2, CD3E, CD3G, CD5, EDF1, FTL, PTEN, PTPN2, PTPN6, PTPRC, PTPRCAP, RPS23, RTRAF, SERF2, SLC38A1, SMAD2, SOCS1, SRP14, SRSF9, SUB1, TET2, TIGIT, TRAC, and TRIM28.

[0015] In some embodiments, the safe harbor locus is selected from any one of the integration sites in Table 4, which are referred to as GS88, GS89, GS90, GS91, GS92, GS93, GS94, GS95, GS96, GS97, GS98, GS99, GS100, GS101, GS102, GS103, GS104, GS105, GS106, GS107, GS108, GS109, GS110, GS111, GS112, GS113, GS114, GS115, GS116, GS117, GS118, GS119, and GS120. In some embodiments, the safe harbor locus is selected from any one of the integration sites in Table 4, referred to as GS91, GS92, GS93, GS94, GS95, GS96, GS100, GS101, GS102, GS103, GS104, and GS105. In some embodiments, the safe harbor locus is selected from any one of the integration sites in Table 4, referred to as GS103, GS104, and GS105. In some embodiments, the safe harbor locus is selected from any one of the integration sites in Table 4, referred to as GS94, GS95, and GS96. In some embodiments, the safe harbor locus is the GS94 integration site in Table 4. In some embodiments, the safe harbor locus is selected from any one of the integration sites in Table 4, referred to as GS100, GS101, and GS102. In some embodiments, the safe harbor locus is the GS102 integration site in Table 4. In some embodiments, the safe harbor locus is selected from one of the integration sites in Table 4, referred to as GS91, GS92, and GS93.

[0016] In some embodiments, the transgene encodes a recombinant protein, optionally a therapeutic agent. In some embodiments, the transgene encodes a chimeric antigen receptor (CAR). In some embodiments, at least one sequence includes an exogenous promoter, which is operably ligated to the transgene. In some embodiments, the exogenous promoter is the EF1a promoter. In some embodiments, the cells are stem cells, human cells, primary cells, hematopoietic cells, adaptive immune cells, innate immune cells, T cells, or T cell precursors. In some embodiments, at least one sequence is inserted using homologous recombination repair. In some embodiments, at least one sequence is inserted using homologous recombination-independent specific insertion. In some embodiments, at least one sequence is inserted using one or more guide ribonucleic acids (gRNAs) and one or more Cas9 endonucleases.

[0017] In some embodiments, one or more gRNAs include one of sequence numbers 1 to 120. In some embodiments, one or more gRNAs include one of sequence numbers 91 to 96 and 100 to 105. In some embodiments, the gRNA includes sequence number 94 or sequence number 102. In some embodiments, the gRNA includes sequence number 94. In some embodiments, the gRNA includes sequence number 102.

[0018] In another embodiment, the present disclosure provides a method for editing T cells, comprising contacting the T cells with one or more guide ribonucleic acids (gRNAs), at least one sequence encoding a transgene, and one or more Cas9 endonucleases, wherein the one or more gRNAs and Cas9 endonucleases facilitate the insertion of at least one sequence into chromosomal DNA within a safe harbor locus, and the safe harbor locus is selected from one or more sgRNA target loci of Table 4.

[0019] In some embodiments, one or more gRNAs include a sequence selected from any one of the sgRNA sequences in Table 4. In some embodiments, one or more gRNAs include any one of SEQ ID NOs. 1 to 120. In some embodiments, one or more gRNAs include any one of SEQ ID NOs. 91 to 96 and 100 to 105. In some embodiments, the gRNA includes SEQ ID NOs. 94 or SEQ ID NOs. 102. In some embodiments, the gRNA includes SEQ ID NOs. 102.

[0020] In some embodiments, the target loci are chr10:33130000~33140000, chr10:72290000~72300000, chr11:128340000~128350000, chr11:65425000~65427000 (NEAT1), chr15:92830000~92840000 , chr16:11220000~11230000, chr2:87460000~87470000, chr3:186510000~186520000, chr3:59450000~59460000, chr8:127980000~128000000, and chr9:7970000~7980000. In some embodiments, the target locus is selected from chr10:72290000~72300000, chr11:128340000~128350000, chr15:92830000~92840000, and chr16:11220000~11230000. In some embodiments, the target locus is chr11:128340000~128350000. In some embodiments, the target locus is chr15:92830000~92840000. In some embodiments, the target locus is a gene selected from APRT, B2M, CAPNS1, CBLB, CD2, CD3E, CD3G, CD5, EDF1, FTL, PTEN, PTPN2, PTPN6, PTPRC, PTPRCAP, RPS23, RTRAF, SERF2, SLC38A1, SMAD2, SOCS1, SRP14, SRSF9, SUB1, TET2, TIGIT, TRAC, and TRIM28.

[0021] In some embodiments, the safe harbor locus is selected from any one of the integration sites in Table 4, which are referred to as GS88, GS89, GS90, GS91, GS92, GS93, GS94, GS95, GS96, GS97, GS98, GS99, GS100, GS101, GS102, GS103, GS104, GS105, GS106, GS107, GS108, GS109, GS110, GS111, GS112, GS113, GS114, GS115, GS116, GS117, GS118, GS119, and GS120. In some embodiments, the safe harbor locus is selected from any one of the integration sites in Table 4, referred to as GS91, GS92, GS93, GS94, GS95, GS96, GS100, GS101, GS102, GS103, GS104, and GS105. In some embodiments, the safe harbor locus is selected from any one of the integration sites in Table 4, referred to as GS103, GS104, and GS105. In some embodiments, the safe harbor locus is selected from any one of the integration sites in Table 4, referred to as GS94, GS95, and GS96. In some embodiments, the safe harbor locus is the GS94 integration site in Table 4. In some embodiments, the safe harbor locus is selected from any one of the integration sites in Table 4, referred to as GS100, GS101, and GS102. In some embodiments, the safe harbor locus is the GS102 integration site in Table 4. In some embodiments, the safe harbor locus is selected from one of the integration sites in Table 4, referred to as GS91, GS92, and GS93.

[0022] In another embodiment, the present disclosure provides an ex vivo method for obtaining an engineered cell or population thereof, comprising (a) obtaining a cell and (b) genetically modifying the cell by inserting at least one sequence encoding a transgene into a safe harbor locus, wherein the safe harbor locus is selected from any one of the sgRNA target loci of Table 4.

[0023] In some embodiments, obtaining the cells includes (i) collecting a tissue sample from a subject, (ii) isolating the cells from the tissue sample, and (iii) culturing the cells in vitro. In some embodiments, the tissue sample is a blood sample. In some embodiments, the cells are stem cells, human cells, primary cells, hematopoietic cells, adaptive immune cells, innate immune cells, T cells, or T cell progenitor cells (T cell precursors). In some embodiments, at least one sequence is inserted using homologous recombination repair. In some embodiments, at least one sequence is inserted using homology-independent specific insertion.

[0024] In some embodiments, genetically modifying in step (b) includes contacting the cells with one or more guide ribonucleic acids (gRNAs), at least one sequence, and one or more Cas9 endonucleases, wherein the one or more gRNAs and Cas9 endonucleases facilitate insertion of at least one sequence into chromosomal DNA within a safe harbor locus. In some embodiments, the one or more gRNAs include a sequence selected from any one of the sgRNA sequences of Table 4.

[0025] In some embodiments, the transgene encodes a recombinant protein, optionally a therapeutic agent. In some embodiments, the transgene encodes a chimeric antigen receptor (CAR). In some embodiments, at least one sequence includes an exogenous promoter, and the exogenous promoter is operably linked to the transgene. In some embodiments, the exogenous promoter is the EF1a promoter.

[0026] In yet another aspect, the present disclosure provides a method of treating a subject having a disease or at risk of having a disease, the method comprising administering to the subject an effective amount of the engineered cells, population thereof, or composition described herein. In some embodiments, the cells, population thereof, or composition are administered to the subject by injection.

[0027] In yet another aspect, the present disclosure provides a method of treating a subject having a disease or at risk of having a disease, the method comprising: (a) performing any one of the methods described above; and (b) administering to the subject an effective amount of a composition comprising a cell or population thereof. In some embodiments, the composition is administered to the subject by injection. In some embodiments, the disease is cancer. In some embodiments, the disease is a blood cancer.

[0028] In another aspect, the present disclosure provides a method of identifying a safe harbor locus, the method comprising: (a) identifying genes or non-coding regions within a chromosome that exceed a threshold level of expression and / or a threshold level of chromatin accessibility over the developmental state of a cell; (b) generating a linear model that shows the correlation between the genes or non-coding regions from step (a) and knock-in (KI) efficiency and estimates the KI efficiency of any gene or coding region on the chromosome; and (c) selecting a safe harbor locus based on threshold parameters, wherein the safe harbor locus is selected for inserting at least one sequence encoding a transgene into a cell.

[0029] In some embodiments, the threshold parameters include one or more of the following: stable expression of the transgene, gene knockout conferring a benefit to cellular function, no known function within the cell, stable transgene expression in vitro with or without CD3 / CD28 stimulation, negligible off-target cleavage detected by iGuide-Seq or CRISPR-Seq, fewer off-target cleavage compared to other loci detected by iGuide-Seq or CRISPR-Seq, negligible transgene-independent cytotoxicity, negligible transgene-independent cytokine expression, negligible transgene-independent chimeric antigen receptor expression, negligible deregulation or silencing of neighboring genes, and location outside of cancer-related genes. In some embodiments, stable expression of the transgene at a safe harbor locus is a 2x or less expression change over at least 1, 2, 3, 4, 5, 6, or 7 days, and the expression change is measured by the mean fluorescence intensity of a reporter gene encoded by at least one sequence. In some embodiments, chromatin accessibility is measured using a transposase-accessible chromatin assay with sequencing (ATAC-seq). In some embodiments, expression levels across cell developmental states are measured using RNA sequencing (RNA-seq).

[0030] In some embodiments, the cells are stem cells, human cells, primary cells, hematopoietic cells, adaptive immune cells, innate immune cells, T cells, or T cell precursors. In some embodiments, the linear model has a coefficient of determination of at least 30% (R). 2 It has a value.

[0031] In yet another aspect, the present disclosure provides engineered cells, compositions, gRNAs, or methods described herein, wherein insertion within a safe harbor locus increases the cytotoxicity of diseased cells.

[0032] In yet another aspect, the present disclosure provides engineered cells, compositions, gRNAs, or methods described herein, wherein the knock-in efficiency at a safe harbor locus is higher compared to other locations along the chromosome. [Brief explanation of the drawing]

[0033] These and other features, aspects, and advantages of the present invention will be better understood with reference to the following description and accompanying drawings.

[0034] [Figure 1-1] Figure 1 includes a schematic diagram illustrating the methodology used in some embodiments to identify safe harbor loci in this disclosure. [Figure 1-2] Refer to the explanation in Figure 1-1.

[0035] [Figure 2] Figures 2A–C include schematic diagrams showing the top three safe harbor loci known in the art: AAVS1 (Figure 2A), CCR5 (Figure 2B), and Rosa26 (Figure 2C). These figures were taken from Sadelain, M., et al. (2012). Safe harbors for the integration of new DNA in the human genome. Nature reviews Cancer, 12(1), 51–58 (the relevant disclosure is incorporated herein by reference in its entirety).

[0036] [Figure 3] This includes a schematic diagram outlining the data described in Roth, TL, et al. 2019. Rapid discovery of synthetic DNA sequences to rewrite endogenous T cell circuits. bioRxiv, 604561 (its related disclosure is incorporated herein by reference in its entirety).

[0037] [Figure 4A] Figures 4A-4B include heatmaps of samples clustered based on activation state and cell type, generated using processed RNA-seq data. Figure 4A includes a heatmap of samples generated using processed RNA-seq data. [Figure 4B] Figure 4B includes a heatmap sample generated using processed RNA-seq data, showing clustering of approximately 20k genes.

[0038] [Figure 5A] Figures 5A–5B include plots generated using processed RNA-seq data. Figure 5A includes a plot showing a direct correlation between transcriptional expression data from Roth, TL, et al. 2019 and transcriptional expression data generated by the inventors of this disclosure. [Figure 5B] Figure 5B includes a heatmap showing clusters of the top 10% expressed genes.

[0039] [Figure 6] Includes a heatmap of the sample generated using processed ATAC-seq data.

[0040] [Figure 7A] Includes plots showing signal enhancement at transcription start sites (TSS), generated using processed ATAC-seq data from the coding region. [Figure 7B] Includes a plot showing signal enhancement in the peak size distribution, generated using processed ATAC-seq data from the coded region.

[0041] [Figure 8] Includes a plot showing the open chromatin region around the TRAC gene locus.

[0042] [Figure 9] Includes plots showing the KI (knock-in) efficiency of coding regions / genes with GFP as a reporter.

[0043] [Figure 10] Includes plots showing the KI efficiency of coding regions / genes with tNGFR as reporters.

[0044] [Figure 11] This includes plots showing the scaled KI efficiency for 90 genes using d2 (day 2) RNA-seq data, d4 (day 4) RNA-seq data, and ATAC-seq data, which are used in the predictive linear model.

[0045] [Figure 12] Includes a plot showing the chromatin accessibility of top candidate non-coding regions, measured using ATAQ sequencing.

[0046] [Figure 13A] Includes a plot showing the cell count of GFP controls used to evaluate candidate KI loci. [Figure 13B] Includes pmax(GFP_high) readings of the GFP control used to evaluate candidate KI loci.

[0047] [Figure 14A] Includes a plot showing the maximum episomal GFP expression (GFP_high) reading for non-targeted controls. [Figure 14B] Includes cell counts of untargeted controls from donors 1, 2, and 3.

[0048] [Figure 15] Includes cell counts and maximum GFP expression (GFP_high) readings for WT control.

[0049] [Figure 16] This includes plots showing cell counts and maximum GFP expression (GFP_high) readings when construct expression is driven by an endogenous promoter using sgRNA5 targeting the B2M safe harbor locus.

[0050] [Figure 17] This includes plots showing cell counts and maximum GFP expression (GFP_high) readings when construct expression is driven by the EF1a promoter using sgRNA5 targeting the B2M safe harbor locus.

[0051] [Figure 18-1] Figure 18 includes a plot showing cell counts and maximum GFP expression (GFP_high) readings when construct expression is driven by an endogenous promoter using sgRNA79 to target the TRAC safe harbor locus. [Figure 18-2] See the explanation in Figure 18-1.

[0052] [Figure 19-1] Figure 19 includes a plot showing cell counts and maximum GFP expression (GFP_high) readings when construct expression is driven by an exogenous promoter using sgRNA79 targeting the TRAC safe harbor locus. [Figure 19-2] See the explanation in Figure 19-1.

[0053] [Figure 20-1] Figure 20 includes plots showing TCR (T cell receptor) vs. GFP across all donors and time points when the construct is driven by an endogenous promoter using sgRNA79. [Figure 20-2] Refer to the explanation in Figure 20-1. [Figure 20-3] Refer to the explanation in Figure 20-1. [Figure 20-4] Refer to the explanation in Figure 20-1.

[0054] [Figure 21-1]Figure 21 includes plots showing TCR vs. GFP across all donors and time points when the construct is driven by an exogenous promoter using sgRNA79. [Figure 21-2] See the explanation in Figure 21-1. [Figure 21-3] See the explanation in Figure 21-1.

[0055] [Figure 22-1] Figure 22 includes a plot showing cell counts and maximum GFP expression (GFP_high) readings when construct expression is driven by an endogenous promoter using sgRNA83 targeting the TRAC safe harbor locus. [Figure 22-2] See the explanation in Figure 22-1.

[0056] [Figure 23] This includes plots showing cell counts and maximum GFP expression (GFP_high) readings when construct expression is driven by an exogenous promoter, using sgRNA83 targeting the TRAC safe harbor locus.

[0057] [Figure 24-1] Figure 24 includes plots showing TCR vs. GFP across all donors and time points when the construct is driven by an endogenous promoter using sgRNA83. [Figure 24-2] See the explanation in Figure 24-1. [Figure 24-3] See the explanation in Figure 24-1. [Figure 24-4] See the explanation in Figure 24-1.

[0058] [Figure 25-1] Figure 25 includes plots showing TCR vs. GFP across all donors and time points when the construct is driven by an exogenous promoter using sgRNA83. [Figure 25-2] See the explanation in Figure 25-1. [Figure 25-3]See the explanation in Figure 25-1.

[0059] [Figure 26] The diagram includes plots illustrating potential sources of variation observed between the replica and the donor (e.g., edge effects and electroporation errors).

[0060] [Figure 27] This includes plots illustrating potential sources of variation observed between the replica and the donor, such as those related to inherent differences between donors.

[0061] [Figure 28] The data includes plots illustrating potential sources of variation observed between the replica and the donor, such as those related to gating errors.

[0062] [Figure 29-1] Figure 29 includes plots showing the mean GFP fluorescence intensity (GFP MFI) and KI efficiency for top KI loci evaluated by endogenous promoters.

[0063] [Figure 29-2] See the explanation in Figure 29-1. [Figure 30-1] Figure 30 includes plots showing the mean GFP fluorescence intensity (GFP MFI) and KI efficiency for the top KI loci evaluated by the EF1a promoter. [Figure 30-2] Refer to the explanation in Figure 30-1.

[0064] [Figure 31A] Figures 31A-31C include plots showing all significant KI loci (superficial KI loci) evaluated using both the endogenous and EF1a promoters. Figure 31A includes a plot showing that expression from the EF1a promoter was approximately 10 times higher than expression from the endogenous promoter. [Figure 31B-1]Figure 31B includes a plot showing all significant KI loci (top KI loci) evaluated using endogenous and EF1a promoters. Figure 31B shows the top KI loci ranked by GFP MFI at week 3. [Figure 31B-2] Refer to the explanation in Figure 31B-1. [Figure 31C-1] Figure 31C includes a plot showing all significant KI loci (top KI loci) evaluated using endogenous and EF1a promoters. Figure 31C shows the top integrated loci ranked by GFP MFI (weeks 3 and 4; donors 1-3). [Figure 31C-2] Refer to the explanation in Figure 31C-1.

[0065] [Figure 32A] Includes plots showing several target gene loci and their measured transgene expression levels. [Figure 32B] Includes plots showing control and insertion transgene (Prime Receptor (PrimeR)) and TCR expression at GS94, GS102, and TRAC loci.

[0066] [Figure 33] Figure 33A includes a plot showing the PrimeR levels measured for the indicated integration site. Figure 33B includes a schematic diagram showing the GS94 integration site on chromosome 11.

[0067] [Figure 34A] Includes plots showing CAR induction and primeR expression in manipulated T cells after co-culture with K562-CD19 cells for 48 hours. [Figure 34B] Includes plots showing cytotoxicity and cytokine secretion levels of engineered T cells co-cultured with K562-CD19 / MSLN cells for 48 hours.

[0068] [Figure 35]Figure 35A includes a schematic diagram showing an experimental outline for evaluating the effect of the integration site on cytotoxicity. Figure 35B includes a plot showing the measured cytotoxicity of engineered T cells co-cultured with K562 CD19+ / MSLN+ or K562 CD19- / MSLN+ cells for 48 hours.

[0069] [Figure 36] Figure 36A includes a schematic diagram showing an experimental overview for evaluating the effect of integration sites on cytokine secretion. Figure 36B includes a plot showing measured cytokine levels of engineered T cells co-cultured with K562 CD19+ / MSLN+ cells for 48 hours.

[0070] [Figure 37] Includes a schematic diagram showing in vitro experiments performed to determine the effect of integration sites on primeR-independent CAR expression. "Flow" refers to flow cytometry, "restim" refers to repeated CD3 / CD28 stimulation of engineered T cells, and "EP" refers to electroporation.

[0071] [Figure 38A] Figures 38A and 38B include plots showing the stability of PrimeR expression over time when using the indicated embedding sites. "Flow" refers to flow cytometry, "restim" refers to repeated CD3 / CD28 stimulation of engineered T cells, and "EP" refers to electroporation. [Figure 38B] In Figure 38B, PrimeR expression is normalized to expression using the TRAC integration site.

[0072] [Figure 39A] Includes a schematic diagram illustrating the iGuide-Seq assay technique. [Figure 39B] For the indicated integration site, the iGuide Seq assay was used, and a plot showing on-target efficiency is included. [Figure 39C]Includes a schematic diagram from iGuide-Seq analysis showing that GS94 did not have reproducible estimated off-targets across two donors.

[0073] [Figure 40] Includes a schematic diagram illustrating the iGuide-Seq workflow and data.

[0074] [Figure 41] Includes plots showing rhAmp-seq analysis of estimated off-target sites identified by iGUIDE-seq and elevation prediction.

[0075] [Figure 42] This includes plots showing RNA-seq analysis of cells using GS94, GS102, and TRAC knock-ins of the CD19 / MSLN circuit. A scatter plot of gene expression in cells with integration at the GS94 locus (y-axis) is shown in comparison to cells with integration at either the TRAC or GS102 locus (x-axis) in two donors. Yellow dots correspond to ETS1 and FLI1. Genes found to be differentially expressed using edgeR are shown in blue (change scalar > 0, FDR corrected p-value < 0.01, mean counts per million at least 2 across the compared conditions).

[0076] [Figure 43] GS94 includes a plot showing the absence of cytokine-independent growth in cells with the CD19 / MSLN circuit KI.

[0077] [Figure 44] The diagram shows an 8.3kb cassette inserted into the GS94 safe harbor locus.

[0078] [Figure 45] This shows the expression of an 8.3kb transgene circuit containing the priming receptor and CAR in K562 cells.

[0079] [Figure 46] This indicates that non-viral editing generated T cells that were not yet differentiated. [Modes for carrying out the invention]

[0080] Detailed explanation This disclosure provides safe harbor loci and methods for identifying safe harbor loci that exhibit high integration efficiency (e.g., high knock-in (KI) efficiency), high and consistent levels of transgene expression, and such advantages independent of the T cell activation / differentiation state. In some embodiments, safe harbor loci also exhibit minimal or no disruption to the function and / or ability of T cells for product manufacturing. In some embodiments, these loci are useful for the effective and safe integration and expression of transgenes in T cells (e.g., CAR T therapy). In some embodiments, the methods described herein may be used to identify safe harbor loci for transgene insertion in other cell types.

[0081] Figure 1 illustrates the overall approach used by the inventors of this disclosure to identify safe harbor loci. In some embodiments, this disclosure includes identifying intragenomic and non-coding region genes that have sustained expression in therapeutic cells (e.g., T cells) and provides a method for predicting candidate integration sites using a predictive model of KI efficiency as a function of T cell chromatin state and computer analysis. The method further includes evaluating candidate integration sites for actual KI efficiency, sustained levels of transgene expression of the transgene, and minimal disruption to the therapeutic cell phenotype (e.g., T cell function and / or ability for the expansion and production of therapeutic products). In some embodiments, safe harbor loci allow for the integration of transgenes driven by endogenous promoters. In some embodiments, safe harbor loci allow for the integration of transgenes driven by exogenous promoters (e.g., EF1a promoter).

[0082] To facilitate understanding of this disclosure, several terms and phrases are defined below. Unless otherwise defined herein, scientific and technical terms used in this application have the meanings generally understood by those skilled in the art. In general, the terms and techniques used in relation to pharmacology, cell and tissue culture, molecular biology, cell and cancer biology, neurobiology, neurochemistry, virology, immunology, microbiology, genetics, and protein and nucleic acid chemistry as described herein are well known and commonly used in the art. In case of any conflict, this specification, including its definitions, shall prevail.

[0083] Unless otherwise defined, all technical terms, notations, and other scientific terms used herein are intended to have meanings generally understood by those skilled in the art. Where applicable, terms having generally understood meanings are defined herein for clarity and / or for easy reference, and the inclusion of such definitions herein should not necessarily be interpreted as representing a difference from the generally understood meaning in the art. The techniques and procedures described or referenced herein are generally well understood and commonly used by those skilled in the art using ordinary methodologies, such as the widely used molecular cloning methodology described, for example, Sambrook et al., Molecular Cloning: A Laboratory Manual 4th ed. (2012), Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY. Where necessary, procedures involving the use of commercially available kits and reagents are generally performed according to the protocols and conditions defined by the manufacturer unless otherwise specified.

[0084] As used herein, the singular forms “a,” “an,” and “the” refer to multiple objects unless the context clearly indicates otherwise. Terms such as “include” and “such as” are intended to convey inclusion without limitation unless otherwise specified.

[0085] As used herein, the term “comprising” also specifically includes embodiments that “consist of” and “essentially consist of” the enumerated elements, unless otherwise specified.

[0086] The term “approximately” indicates and encompasses both the value and the range above and below that value. In certain embodiments, the term “approximately” indicates a specified value ±10%, ±5%, or ±1%. In certain embodiments, where applicable, the term “approximately” indicates the standard deviation of the specified value(s) ±1 of that value(s).

[0087] As used herein, the term “gene” refers to the basic unit of heredity, consisting of a segment of DNA arranged along a chromosome that codes for a particular protein or segment of a protein. A gene typically includes a promoter, a 5' untranslated region, one or more coding sequences (exons), an intron (optionally), and a 3' untranslated region. A gene may further include terminators, enhancers, and / or silencers.

[0088] As used herein, the term “locus” refers to a specific, fixed physical location on a chromosome where a gene or genetic marker is located.

[0089] As used herein, the term “target locus” refers to a locus on a chromosome where a safe harbor locus can be used for sequence insertion. A target locus may consist of multiple potential safe harbor loci (integration sites). Examples of target loci are listed in Table 4 as sgRNA target loci. The notation used for sgRNA target loci in Table 4 refers to the genomic region of the target locus, defined by the chromosome of the target locus and the coordinate range of that locus. For example, chr10:33130000~33140000 refers to a target locus on Chr10 (chromosome 10), starting at coordinate 33130000 and ending at coordinate 33140000.

[0090] The term “safe harbor locus” refers to a locus into which a gene or gene element can be incorporated without interrupting the expression or regulation of adjacent genes. These safe harbor loci are also referred to as safe harbor sites (SHS). As used herein, a safe harbor locus refers to an “incorporation site” or “knock-in site” into which a sequence encoding a transgene, as defined herein, can be inserted. In some embodiments, the insertion occurs by substitution of a sequence located at the integration site. In some embodiments, the insertion occurs without substitution of a sequence at the integration site. Examples of intended integration sites are shown in Table 4.

[0091] As used herein, the term “insertion” refers to a nucleotide sequence that is incorporated into (inserted into) a safe harbor site. “Insertion” can be used to refer to a gene or genetic element incorporated into a safe harbor site, for example, by homology-directed repair (HDR), CRISPR / Cas9 genome editing, or other methods for inserting nucleotide sequences into genomic regions known to those skilled in the art.

[0092] The "CRISPR / Cas" system refers to a broad class of bacterial systems for defense against foreign nucleic acids. CRISPR / Cas systems are found in a wide range of fungi and archaea. The CRISPR / Cas system includes type I, type II, and type III subtypes. The wild-type type II CRISPR / Cas system utilizes Cas9, an RNA-mediated nuclease in a complex with guide and activating RNAs, to recognize and cleave foreign nucleic acids. Guide RNAs possessing activity in both the guide and activating RNAs are also known in the art. In some cases, such dual-active guide RNAs are referred to as small guide RNAs (sgRNAs).

[0093] Cas9 homologs are found in a wide variety of fungi, including but not limited to the following taxa of bacteria: Actinobacteria, Aquificae, Bacteroidetes-Chlorobi, Chlamydiae-Verrucomicrobia, Chloroflexi, Cyanobacteria, Firmicutes, Proteobacteria, Spirochaetes, and Thermotogae. An exemplary Cas9 protein is the Streptococcus pyogenes Cas9 protein. Additional Cas9 proteins and their homologs are described, for example, in Chylinksi, et al., RNA Biol. 2013 May 1;10(5):726-737, Nat. Rev. Microbiol. 2011 June;9(6):467-477, Hou, et al., Proc Natl Acad Sci US A. 2013 Sep 24;110(39):15644-9, Sampson et al., Nature. 2013 May 9;497(7448):254-7, and Jinek, et al., Science. 2012 Aug 17;337(6096):816-21. The Cas9 nuclease domain can be optimized for efficient activity or enhanced stability in host cells.

[0094] As used herein, the term “Cas9” refers to an RNA-mediated nuclease (e.g., of bacterial or archaeal origin, or derived therefrom). Exemplary RNA-mediated nucleases include, but are not limited to, the aforementioned Cas9 protein and its homologs, and CPF1 (see, for example, Zetsche et al., Cell, Volume 163, Issue 3, pp. 759-771, 22 October 2015). Similarly, as used herein, the terms “Cas9 ribonucleoprotein” complex, etc., refer to a complex between the Cas9 protein and crRNA (e.g., guide RNA or small guide RNA), the Cas9 protein and transactivating crRNA (tracrRNA), the Cas9 protein and small guide RNA, or a combination thereof (e.g., a complex containing the Cas9 protein, tracrRNA, and crRNA guide RNA).

[0095] As used herein, the terms “T lymphocyte” and “T cell” are interchangeable and refer to cells that have completed maturation in the thymus and identified a particular foreign antigen in the body. These terms also refer to the major leukocyte types that have various roles in the immune system, including the activation and inactivation of other immune cells. T cells can be any T cells, such as cultured T cells, e.g., primary T cells, or T cells derived from cultured T cell lines, e.g., Jurkat, SupT1, etc., or mammalian T cells. T cells can be CD3+ cells. T cells can be any type of T cell, including, but are not limited to, any type of T cell, such as CD4+ / CD8+ double-positive T cells, CD4+ helper T cells (e.g., Th1 and Th2 cells), CD8+ T cells (e.g., cytotoxic T cells), which can be peripheral, including blood mononuclear cells (PBMCs), peripheral blood leukocytes (PBLs), tumor-infiltrating lymphocytes (TILs), memory T cells, naive T cells, regulatory T cells, γδ T cells, etc. It can be any T cell at any stage of development. Additional types of helper T cells include Th3 (Treg) cells, Th17 cells, Th9 cells, or Tfh cells. Additional types of memory T cells include cells such as central memory T cells (Tcm cells) and effector memory T cells (Tem cells and TEMRA cells). T cells can also refer to genetically modified T cells, such as T cells modified to express a T cell receptor (TCR) or chimeric antigen receptor (CAR). T cells can also differentiate from stem cells or precursor cells (e.g., progenitor cells).

[0096] "CD4+ T cells" refer to a subset of T cells that express CD4 on their surface and are involved in cellular immune responses. CD4+ T cells are characterized by a post-stimulation secretion profile that may include the secretion of cytokines such as IFN-γ, TNF-α, IL-2, IL-4, and IL-10. "CD4" is a 55kD glycoprotein originally defined as a differentiation antigen on T lymphocytes, but has also been found on other cells, including monocytes / macrophages. The CD4 antigen is a member of the immunoglobulin superfamily and has been suggested as an associative recognition element in MHC (major histocompatibility complex) class II restriction immune responses. On T lymphocytes, the CD4 antigen defines a helper / inducer subset.

[0097] "CD8+ T cells" refer to a subset of T cells that express CD8 on their surface, are MHC class I restricted, and function as cytotoxic T cells. The "CD8" molecule is a differentiation antigen present on thymocytes, as well as on cytotoxic and suppressive T lymphocytes. The CD8 antigen is a member of the immunoglobulin superfamily and is an associative recognition element in major histocompatibility complex class I restriction interactions.

[0098] As used herein, the term “ex vivo” generally includes experiments or measurements conducted in or on living tissue, preferably in an artificial environment outside of living tissue, preferably with minimal differences from natural conditions.

[0099] As used herein, the term “construct” refers to a complex of molecules, including macromolecules or polynucleotides.

[0100] As used herein, the term “integration” refers to the process of stably inserting one or more nucleotides of a construct into the cellular genome, i.e., covalently bonding them to a nucleic acid sequence within the cell’s chromosomal DNA. It may also refer to a nucleotide deletion at the site of integration. If there is a deletion at the insertion site, “integration” may further include the deletion of an endogenous sequence or nucleotide substitution with one or more inserted nucleotides.

[0101] As used herein, the term “exogenous” refers to a molecule or activity that is introduced into a host cell and is not native to that cell. This molecule may be introduced, for example, by the introduction of coding nucleic acids into the host genetic material, for example, by integration into the host chromosome, or as non-chromosomal genetic material such as a plasmid. Thus, when used in relation to the expression of coding nucleic acids, the term refers to the introduction of coding nucleic acids into cells in an expressible form. The term “endogenous” refers to a molecule or activity that is present in the host cell under native, unedited conditions. Similarly, when used in relation to the expression of coding nucleic acids, the term refers to the expression of coding nucleic acids that are contained within the cell and not introduced exogenously.

[0102] As used herein, “polynucleotide donor construct” refers to a nucleotide sequence (e.g., a DNA sequence) that is genetically inserted into a polynucleotide and is exogenous to that polynucleotide. A polynucleotide donor construct is transcribed into RNA and optionally translated into a polypeptide. A polynucleotide donor construct may include a prokaryotic sequence, a cDNA derived from eukaryotic mRNA, a genomic DNA sequence derived from eukaryotic (e.g., mammalian) DNA, and a synthetic DNA sequence. For example, a polynucleotide donor construct may be a miRNA, shRNA, a native polypeptide (i.e., a naturally occurring polypeptide) or a fragment thereof, or a variant polypeptide (e.g., a native polypeptide having less than 100% sequence identity with the native polypeptide) or a fragment thereof.

[0103] As used herein, the term “transgene” refers to a polynucleotide that has been translocated from one organism to another, either naturally or by one of several genetic engineering techniques. It is optionally translated into a polypeptide. It is optionally translated into a recombinant protein. A “recombinant protein” is a protein encoded by a gene (recombinant DNA) that has been cloned in a system that supports gene expression and messenger RNA translation (see expression system). Recombinant proteins may be therapeutic agents, for example, proteins that treat diseases or disorders disclosed herein. As used herein, transgene may refer to a polynucleotide that codes for a polypeptide. Transgene may also refer to non-coding sequences such as shRNA, miRNA, and miR, but are not limited to these.

[0104] The terms "protein," "polypeptide," and "peptide" are used interchangeably in this specification.

[0105] As used herein, the term “operably ligated” refers to a nucleic acid sequence being bound to a single nucleic acid fragment such that the function of one is influenced by the function of the other. For example, if a promoter can influence the expression of a coding sequence or functional RNA (i.e., the coding sequence or functional RNA is under transcriptional control by the promoter), then the promoter is operably ligated to it. A coding sequence can be operably ligated to a control sequence in both sense-oriented and antisense-oriented orientations.

[0106] As used herein, the term “cell developmental state” refers to, for example, a cell in an inactive state, an actively expressed state, a differentiating state, an aged state, etc. The cell developmental state may also refer to a progenitor state of cell (e.g., a T cell progenitor or T cell precursor).

[0107] Where used, the term “encodes” refers to a nucleic acid sequence that codes for a protein or polypeptide of interest. The nucleic acid sequence can be either a DNA or RNA molecule. In a preferred embodiment, the molecule is a DNA molecule. In another preferred embodiment, the molecule is an RNA molecule. When present as an RNA molecule, it includes a sequence that instructs the ribosomes of a host cell to begin translation (e.g., a start codon, ATG) and a sequence that instructs the ribosomes to terminate translation (e.g., a stop codon). Between the start codon and the stop codon is an open reading frame (ORF). Such terminology is known to those skilled in the art.

[0108] The term "insertion" refers to the manipulation of nucleotide sequences to introduce non-natural sequences. This is done, for example, by using restriction enzymes and ligases, thereby incorporating a target DNA sequence, usually encoding a gene of interest, into another nucleic acid molecule by digesting both molecules with the appropriate restriction enzymes to create a compatible overlap, and then joining the molecules together using a ligase. Those skilled in the art are very familiar with such operations, and examples can be found in Sambrook et al. (Sambrook, Fritsch, & Maniatis, "Molecular Cloning: A Laboratory Manual", 2nd ed., Cold Spring Harbor Laboratory, 1989), which is incorporated herein by reference in its entirety, including any figures, drawings and tables.

[0109] As used herein, the term “subject” refers to a mammalian subject. Exemplary subjects include humans, monkeys, dogs, cats, mice, rats, cattle, horses, camels, goats, rabbits, pigs, and sheep. In certain embodiments, the subject is a human. In some embodiments, the subject has a disease or condition that can be treated with the manipulated cells or populations described herein. In some embodiments, the disease or condition is cancer.

[0110] As used herein, the term “promoter” refers to a nucleotide sequence (e.g., a DNA sequence) that can control the expression of a coding sequence or functional RNA. A promoter sequence consists of proximal and more distal upstream elements, the latter of which are often referred to as enhancers. A promoter may be entirely derived from a native gene, composed of different elements from different promoters found in nature, and / or may include synthetic DNA segments. A promoter may be endogenous to the cell of interest, or exogenous to the cell of interest, as intended herein. It is understood by those skilled in the art that different promoters can induce gene expression in different tissues or cell types, or at different developmental stages, or in response to different environmental conditions. As is known in the art, promoters may be selected according to their strength and / or the conditions under which they are active, e.g., constitutive promoters, potent promoters, weak promoters, inducible / repressive promoters, tissue-specific or developmentally regulated promoters, cell cycle-dependent promoters, etc.

[0111] The promoter may be an inductive promoter (e.g., a heat shock promoter, a tetracycline-regulating promoter, a steroid-regulating promoter, a metal-regulating promoter, an estrogen receptor-regulating promoter, etc.). The promoter may be a constitutive promoter (e.g., a CMV promoter, a UBC promoter). In some embodiments, the promoter may be a spatially restricted and / or temporally restricted promoter (e.g., a tissue-specific promoter, a cell-type-specific promoter, etc.). See, for example, U.S. Patent Application No. 15 / 715,068 (this disclosure is incorporated herein by reference in its entirety).

[0112] As intended herein, gene editing may involve knocking in or knocking out a gene (or nucleotide sequence). As used herein, the term “knock-in” refers to the addition of a DNA sequence or fragment thereof to a genome. Such a DNA sequence to be knocked in may include an entire gene or multiple genes, or it may include a regulatory sequence associated with a gene or any of the aforementioned parts or fragments. For example, a polynucleotide donor construct encoding a recombinant protein may be inserted into the genome of a cell containing a mutant gene. In some embodiments, a knock-in strategy involves the replacement of an existing sequence with a provided sequence, e.g., the replacement of a mutant allele with a wild-type copy. On the other hand, the term “knock-out” refers to the removal of a gene or the expression of a gene. For example, a gene may be knocked out by either the deletion or addition of a nucleotide sequence that leads to the disruption of the leading frame. As another example, a gene may be knocked out by replacing a portion of the gene with an irrelevant (e.g., non-coding) sequence.

[0113] As used herein, the term “non-homologous end junction” or NHEJ refers to a cellular process in which a cleavage end or nick end of a DNA strand is directly ligated without the need for a homologous template nucleic acid. NHEJ can result in the addition, deletion, substitution, or combination thereof of one or more nucleotides at the repair site.

[0114] As used herein, “homologous recombination repair” or HDR refers to a cellular process in which a broken or nick end of a DNA strand is repaired by polymerization from a homologous template nucleic acid. Thus, the original sequence is replaced with the template sequence. The homologous template nucleic acid may be provided by a homologous sequence located elsewhere in the genome (sister chromatid, homologous chromosome, or repeating region on the same or different chromosome). Alternatively, an exogenous template nucleic acid can be introduced to obtain a specific HDR-induced alteration of the sequence at a target site. In this way, a specific mutation can be introduced at the break site.

[0115] The terms “vector” and “plasmid” are used interchangeably and, as used herein, refer to polynucleotide vehicles useful for introducing genetic material into cells. Vectors may be linear or circular. Vectors can be integrated into a target genome of a host cell or replicate independently within the host cell. Vectors may include, for example, an origin of replication, a multicloning site, and / or selectable markers. Expression vectors typically contain an expression cassette. Vectors and plasmids include, but are not limited to, integration vectors, prokaryotic plasmids, eukaryotic plasmids, plant synthetic chromosomes, episomes, viral vectors, cosmids, and artificial chromosomes.

[0116] As used herein, the term “expression cassette” refers to a recombinant or synthetically produced polynucleotide construct comprising a regulatory sequence operably linked to a selected polynucleotide in order to facilitate the expression of the selected polynucleotide in a host cell. For example, the regulatory sequence can facilitate the transcription of the selected polynucleotide in a host cell, or the transcription and translation of the selected polynucleotide in a host cell. An expression cassette may be, for example, incorporated into the genome of a host cell or present in an expression vector.

[0117] As used herein, the phrase “subjects requiring it” means subjects who exhibit and / or are diagnosed with one or more symptoms or signs of any of the diseases or disorders described herein.

[0118] "Chemotherapy agents" refer to chemical compounds useful in treating cancer. Examples of chemotherapy agents include "anti-hormone agents" or "endocrine therapy agents" that act to regulate, reduce, block, or inhibit the effects of hormones that can promote cancer growth.

[0119] The term “composition” refers, for example, to a mixture containing the manipulated cells or proteins intended herein. In some embodiments, the composition may contain additional components such as adjuvants, stabilizers, or excipients. The term “composition” or “pharmaceutical composition” refers to a preparation in which the biological activity of the active ingredients contained herein is effective for the treatment of the subject, and which does not contain additional components that are unacceptably toxic to the subject in the amounts provided in the pharmaceutical composition.

[0120] As used herein, the term “effective amount” means a sufficient amount of the compound (e.g., the composition described herein, the cells described herein) to produce a beneficial or desired result. An effective amount may be administered in one or more doses, applications, or dosages and is not intended to be limited to a particular formulation or route of administration. As used herein, the term “to treat” includes any effect that results in improvement of a condition, disease, disorder, etc., or improves its symptoms, such as alleviation, reduction, regulation, improvement, or elimination.

[0121] The terms "to regulate" and "to adjust" refer to reducing or inhibiting the listed variables, or alternatively, activating or increasing them.

[0122] The terms “increase” and “activate” refer to increases of 10%, 20%, 30%, 40%, 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 100%, 2x, 3x, 4x, 5x, 10x, 20x, 50x, 100x, or more in the listed variables.

[0123] The terms “reduce” and “inhibit” refer to a decrease of 10%, 20%, 30%, 40%, 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 2x, 3x, 4x, 5x, 10x, 20x, 50x, 100x, or more in the listed variables.

[0124] Safe Harbor Locus Gene editing therapies include, for example, viral vector integration and site-directed integration. Site-directed integration is a promising alternative to random integration of viral vectors because it reduces the risk of insertional mutagenesis or insertional carcinogenesis (Kolb et al. Trends Biotechnol. 2005 23:399-406, Porteus et al. Nat Biotechnol. 2005 23:967-973, Paques et al. Curr Gen Ther. 2007 7:49-66). However, site-directed integration continues to face challenges such as low knock-in efficiency, the risk of insertional carcinogenesis, instability and / or abnormal expression of adjacent genes or transgenes, and low accessibility (e.g., within 20kB of adjacent genes). These challenges can be addressed in part by identifying and using safe harbor loci or safe harbor sites (SHSs), which are sites where genes or gene elements can be integrated without disrupting the expression or regulation of adjacent genes.

[0125] The most widely used putative human safe harbor site is the AAVS1 site on chromosome 19q, which was initially identified as a site for recurrent adeno-associated virus insertion. Other potential SHSs are being identified based on homology with sites first identified in other species (e.g., human homology of the tolerant mouse Rosa26 locus) or among an increasing number of human genes that appear intrinsically in some contexts. One of this type of putative SHS is the CCR5 chemokine receptor gene, which, when disrupted, confers resistance to human immunodeficiency virus infection. Additional potential genomic SHSs, as with the original mouse Rosa26 locus, have been identified in humans and other cell types based on viral integration site mapping or gene trapping analysis. The top three SHSs, AAVS1, CCR5, and Rosa26, are located in close proximity to many protein-coding genes and regulatory elements. (See Figure 2 from Sadelain, M., et al. (2012)). Safe harbors for the integration of new DNA in the human genome. Nature Reviews Cancer, 12(1), 51-58 (see related disclosure incorporated herein by reference in its entirety).

[0126] AAVS1 (also known as the PPP1R12C locus) on human chromosome 19 is a known SHS for hosting transgenes (e.g., DNA transgenes) with expected function. It is located at position 19q13.42. It has an open chromatin structure and is transcriptionally active. The canonical SHS locus for AAVS1 is chr19:55,625,241~55,629,351. See Pellenz et al. "New Human Chromosomal Sites with "Safe Harbor" Potential for Targeted Transgene Insertion." Human gene therapy vol.30,7(2019):814-828 (its relevant disclosure is incorporated herein by reference). Exemplary AAVS1 target gRNAs and target sequences are shown below. ●AAVS1-gRNA sequence: ggggccactagggacaggatGTTTTAGAGCTAGAAATAGCAAGTTAAAATAAGGCTAGTCCGTTATCAACTTGAAAAAGTGGCACCGAGTCGGTGCTTTTTTT ●AAVS1 target sequence: ggggccactagggacaggat

[0127] Located on chromosome 3 at position 3p21.31, CCR5 encodes the major co-receptor for HIV-1. Disruption of this site in the CCR5 gene has been beneficial in HIV / AIDS treatment, promoting the development of zinc finger nucleases targeting its third exon. The canonical SHS locus of CCR5 is chr3:46,414,443~46,414,942. See Pellenz et al. "New Human Chromosomal Sites with "Safe Harbor" Potential for Targeted Transgene Insertion." Human gene therapy vol.30,7(2019):814-828 (its relevant disclosure is incorporated herein by reference).

[0128] The mouse Rosa26 locus is particularly useful for gene modification because it can be targeted with high efficiency and is expressed in most cell types tested. Irion et al. 2007 ("Identification and targeting of the ROSA26 locus in human embryonic stem cells." Nature biotechnology 25.12(2007):1477-1482 (its relevant disclosure is incorporated herein by reference) identified human ROSA26, the human homolog, at chromosome 3 (position 3p25.3). The canonical SHS locus for human Rosa26 (hRosa26) is chr3:9,415,082~9,414,043. See Pellenz et al. "New Human Chromosomal Sites with "Safe Harbor" Potential for Targeted Transgene Insertion." Human gene therapy vol.30,7(2019):814-828 (its relevant disclosure is incorporated herein by reference).

[0129] Examples of additional safe harbor sites are described in Pellenz et al. “New Human Chromosomal Sites with “Safe Harbor” Potential for Targeted Transgene Insertion.” Human gene therapy vol.30,7(2019):814-828 (the relevant disclosure is incorporated herein by reference).

[0130] This disclosure relates to a method for identifying safe harbor loci that have advantages including, but not limited to, high knock-in efficiency and high transgene expression. An example of application of the method of this disclosure is the identification of safe harbor loci for the insertion of transgenes (e.g., chimeric antigen receptors (CARs)) into T cells. In some embodiments, the safe harbor loci of this disclosure are useful for the insertion of sequences encoding transgenes. In some embodiments, the safe harbor sites enable high transgene expression (sufficient to enable transgene functionality or treatment of the disease of interest) and stable expression of the transgene over days, weeks, or months. In some embodiments, knockout of the gene at the safe harbor locus benefits cellular function, or the gene at the safe harbor locus has no known function within the cell. In some embodiments, safe harbor loci result in stable transgene expression in vitro with or without CD3 / CD28 stimulation, negligible off-target cleavage detected by iGuide-Seq or CRISPR-Seq, fewer off-target cleavage compared to other loci detected by iGuide-Seq or CRISPR-Seq, negligible transgene-independent cytotoxicity, negligible transgene-independent cytokine expression, negligible transgene-independent chimeric antigen receptor expression, negligible deregulation or silencing of neighboring genes, and being located outside of cancer-related genes.

[0131] When used, "neighboring genes" can refer to genes located within approximately 100kB, 125kB, 150kB, 175kB, 200kB, 225kB, 250kB, 275kB, 300kB, 325kB, 350kB, 375kB, 400kB, 425kB, 450kB, 475kB, 500kB, 525kB, and 550kB of the safe harbor locus (integration site).

[0132] In some embodiments, this disclosure envisions an insertion comprising one or more transgenes. The transgenes may encode therapeutic proteins, antibodies, peptides, suicide genes, apoptotic genes, or any other genes of interest. Safe harbor loci identified using the methods described herein allow for transgene incorporation resulting in, for example, enhanced therapeutic properties. These enhanced therapeutic properties, as used herein, refer to the therapeutic properties of enhanced cells compared to typical immune cells of the same normal cell type. For example, NK cells having “enhanced therapeutic properties” have enhanced, improved, and / or increased therapeutic outcomes compared to typical, unmodified, and / or naturally occurring NK cells. Therapeutic properties of immune cells may include, but are not limited to, cell transplantation, transport, homing, viability, self-renewal, persistence, immune response regulation and modulation, survival, and cytotoxicity. Therapeutic properties of immune cells are also manifested by antigen-targeting receptor expression, HLA presentation or absence, resistance to the intratumor microenvironment, induction and immunomodulation of bystander immune cells, improved target specificity by reduction, and resistance to treatments such as chemotherapy.

[0133] As used herein, “insertion size” refers to the length of the nucleotide sequence incorporated into (inserted into) the safe harbor site. In some embodiments, the insertion size includes at least about 100, 200, 300, 400, or 500 base pairs. In some embodiments, the insertion size includes about 500 nucleotides or base pairs. In some embodiments, the insertion size includes up to 0.5, 0.6, 0.7, 0.8, 0.9, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 kbp (kilobase pairs) or sizes in between. In some embodiments, the insert size is greater than 0.5, 0.6, 0.7, 0.8, 0.9, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 kbp or any size between them. In some embodiments, the insert size is in the range of 3 to 15 kbp or any number within that range. In some embodiments, the insert size is in the range of 1.5 to 8.3 kbp or any number within that range. In some embodiments, the insert size is in the range of 1.5 to 15 kbp or any number within that range. In some embodiments, the insert size is in the range of 0.5 to 20 kbp or any number within that range. In some embodiments, the insert size is 0.5-10, 0.6-10, 0.7-10, 0.8-10, 0.9-10, 1-10, 2-10, 3-10, 4-10, 5-10, 6-10, 7-10, 8-10, or 9-10kbp. In some embodiments, the insert size is 0.5-11, 0.6-11, 0.7-11, 0.8-11, 0.9-11, 1-11, 2-11, 3-11, 4-11, 5-11, 6-11, 7-11, 8-11, 9-11, or 10-11kbp. In some embodiments, the insert size is 0.5-12, 0.6-12, 0.7-12, 0.8-12, 0.9-12, 1-12, 2-12, 3-12, 4-12, 5-12, 6-12, 7-12, 8-12, 9-12, 10-12, or 11-12 kbp.In some embodiments, the insert size is 0.5-13, 0.6-13, 0.7-13, 0.8-13, 0.9-13, 1-13, 2-13, 3-13, 4-13, 5-13, 6-13, 7-13, 8-13, 9-13, 10-13, 11-13, or 12-13kbp. In some embodiments, the insert size is 0.5-14, 0.6-14, 0.7-14, 0.8-14, 0.9-14, 1-14, 2-14, 3-14, 4-14, 5-14, 6-14, 7-14, 8-14, 9-14, 10-14, 11-14, 12-14, or 13-14kbp. In some embodiments, the insert size is 0.5-15, 0.6-15, 0.7-15, 0.8-15, 0.9-15, 1-15, 2-15, 3-15, 4-15, 5-15, 6-15, 7-15, 8-15, 9-15, 10-15, 11-15, 12-15, 13-15, or 14-15kbp. In some embodiments, the insertion size is 0.5-16, 0.6-16, 0.7-16, 0.8-16, 0.9-16, 1-16, 2-16, 3-16, 4-16, 5-16, 6-16, 7-16, 8-16, 9-16, 10-16, 11-16, 12-16, 13-16, 14-16, or 15-16 kbp. In some embodiments, the insert size is 0.5-17, 0.6-17, 0.7-17, 0.8-17, 0.9-17, 1-17, 2-17, 3-17, 4-17, 5-17, 6-17, 7-17, 8-17, 9-17, 10-17, 11-17, 12-17, 13-17, or 14-17, 15-17, or 16-17 kbp. In some embodiments, the insert size is 0.5-18, 0.6-18, 0.7-18, 0.8-18, 0.9-18, 1-18, 2-18, 3-18, 4-18, 5-18, 6-18, 7-18, 8-18, 9-18, 10-18, 11-18, 12-18, 13-18, 14-18, 15-18, 16-18, or 17-18 kbp.In some embodiments, the insert size is 0.5-19, 0.6-19, 0.7-19, 0.8-19, 0.9-19, 1-19, 2-19, 3-19, 4-19, 5-19, 6-19, 7-19, 8-19, 9-19, 10-19, 11-19, 12-19, 13-19, 14-19, 15-19, 16-19, 17-19, or 18-19kbp. In some embodiments, the insert size is 0.5-20, 0.6-20, 0.7-20, 0.8-20, 0.9-20, 1-20, 2-20, 3-20, 4-20, 5-20, 6-20, 7-20, 8-20, 9-20, 10-20, 11-20, 12-20, 13-20, 14-20, 15-20, 16-20, 17-20, 18-20, or 19-20 kbp.

[0134] The inserts in this disclosure refer to nucleic acid molecules or polynucleotides inserted into safe harbor sites. In some embodiments, the nucleotide sequence is a DNA molecule, e.g., genomic DNA, or comprises deoxyribonucleotides. In some embodiments, the inserts comprise smaller fragments of DNA, such as plasmids, fosmids, cosmids, bacterial artificial chromosomes (BACs), yeast artificial chromosomes (YACs), and / or plastid DNA, mitochondrial DNA, or DNA isolated in the form of any other subgenome segment of DNA. In some embodiments, the inserts are RNA molecules or comprise ribonucleotides. The nucleotides in the inserts are intended to be naturally occurring nucleotides, unnaturally occurring nucleotides, and modified nucleotides. The nucleotides may be chemically or biochemically modified, or may contain unnatural or derivatized nucleotide bases, as will be readily understood by those skilled in the art. Such modifications include, for example, labeling, methylation, substitution of one or more naturally occurring nucleotides with analogs, and internucleotide modifications. Polynucleotides can be any topological conformation, including single-stranded, double-stranded, partially double-stranded, triple-stranded, hairpin, circular conformation, and other three-dimensional conformations as intended in the art.

[0135] The insert may have coding regions and / or non-coding regions. The insert may include non-coding sequences (e.g., regulatory elements, e.g., promoter sequences). In some embodiments, the insert encodes a transcription factor. In some embodiments, the insert encodes an antigen-binding receptor such as a single receptor, a T cell receptor (TCR), a syn-notch, a CAR, or an mAb. In some embodiments, the insert is an RNAi molecule, including but not limited to miRNA, siRNA, shRNA, etc. In some embodiments, the insert is a human sequence. In some embodiments, the insert is a chimera. In some embodiments, the insert is a polygene / polymodule therapeutic cassette. A polygene / polymodule therapeutic cassette refers to an insert or cassette having one or more receptors (e.g., synthetic receptors), other exogenous protein-coding sequences, non-coding RNAs, transcriptional regulatory elements, and / or insulating sequences, etc.

[0136] Various cell types are intended in this disclosure to have a safe harbor site. Cells containing a safe harbor site as described in this disclosure and / or cells containing an insert in the safe harbor site may be referred to as engineered cells. Cells include, but are not limited to, eukaryotic cells, prokaryotic cells, animal cells, plant cells, fungal cells, etc. Optionally, the cells are mammalian cells, e.g., human cells. In some embodiments, the engineered cells are stem cells, human cells, primary cells, hematopoietic cells, adaptive immune cells, innate immune cells, T cells, or T cell precursors. Non-exclusive examples of immune cells intended in this disclosure include T cells, B cells, natural killer (NK) cells, NKT / iNKT cells, macrophages, myeloid cells, and dendritic cells. Non-limiting examples of stem cells intended in this disclosure include pluripotent stem cells (PSCs), embryonic stem cells (ESCs), induced pluripotent stem cells (iPSCs), embryo-derived embryonic stem cells (ntES; nuclear transfer ES) obtained by nuclear transfer, male germ cells (GS cells), embryonic germ cells (EG cells), hematopoietic stem / precursor stem cells (HSPCs), somatic cells (adult stem cells), angioblasts, neural stem cells, mesenchymal stem cells, and stem cells of other cells (including osteocytes, chondrocytes, myocytes, cardiomyocytes, neurons, tendinocytes, adipocytes, pancreatic cells, hepatocytes, renal cells, and follicular cells, etc.). In some embodiments, the manipulated cells are T cells, NK cells, iPSCs, and HSPCs. In some embodiments, the manipulated cells used in this disclosure are in vitro grown human cell lines (e.g., intentionally immortalized cell lines, cancer cell lines, etc.).

[0137] The method for incorporating the insert into the safe harbor site may be a viral or nonviral delivery technique.

[0138] In some embodiments, nucleic acid sequences are inserted into the genome of manipulated cells by introducing a nucleic acid-containing vector, such as a viral vector. Examples of viral vectors include, but are not limited to, adeno-associated virus (AAV) vectors, retroviral vectors, or lentiviral vectors. In some embodiments, the lentiviral vector is an integrase-deficient lentiviral vector.

[0139] In some embodiments, nucleic acid sequences are inserted into the T cell genome via nonviral delivery. In nonviral delivery methods, the nucleic acid may be naked DNA or may be in a nonviral plasmid or vector. The nonviral delivery technique may be a site-specific insertion technique described herein or known to those skilled in the art. Examples of site-specific techniques for insertion into safe harbor loci include, but are not limited to, homology-dependent operations using nucleases and homologous recombination-independent specific insertions using Cas9. In some embodiments, the nonviral delivery method includes electroporation.

[0140] In some embodiments, the insert is incorporated into the safe harbor site by introducing (a) a target nuclease into the manipulated cell to cleave the target region of the safe harbor site and create an insertion site, and (b) a nucleic acid sequence (insert), and the insert is incorporated into the insertion site by, for example, HDR. Examples of nonviral delivery techniques that can be used in the methods of this disclosure are described in U.S. applications 16 / 568,116 and 16 / 622,843, and these related disclosures are incorporated herein by reference in their entirety.

[0141] Manipulated cells can maintain their undifferentiated state after the insertion of the transgene. In some embodiments, the manipulated cells are undifferentiated. In some embodiments, the manipulated cells are undifferentiated after the insertion of the transgene. In some embodiments, the manipulated cells are CD45RA+ And CCR7 + In some embodiments, after the insertion of the transgene, the manipulated cells are CD45RA + CCR7 + CD27 + That is the case.

[0142] CAR T cell therapy Chimeric antigen receptor (CAR) T cells are T cells that have been genetically engineered to produce artificial T cell receptors for use in immunotherapy. Chimeric antigen receptors are receptor proteins that have been engineered to confer the ability of T cells to target specific proteins. For example, the genetic modification of lymphocytes (e.g., T cells) by incorporating CARs, and the administration of the engineered cells to a target, is an example of “adoptive cell therapy.” As used herein, the term “adoptive cell therapy” refers to cell-based immunotherapy for transfusion of autologous or allogeneic lymphocytes, referred to as T cells or B cells. In this CAR therapy approach, cells are expanded, cultured ex vivo, and genetically modified before transfusion.

[0143] CAR expression allows manipulated T cells to target and bind to specific proteins, such as tumor antigens. In CAR therapy, T cells are collected from the subject and can be autologous T cells from the subject's own blood or from a donor who is not receiving CAR therapy. Once isolated, the T cells are genetically modified with CAR, expanded ex vivo, and administered to the subject (i.e., the patient), for example, by infusion.

[0144] CARs may be introduced into T cells using, for example, viral techniques (e.g., retroviral integration) or site-specific techniques. Site-specific integration of the transgene (e.g., CAR) allows the transgene to be targeted to a safe harbor locus. Examples of site-specific techniques for integration to a safe harbor locus include, but are not limited to, homology-dependent manipulation using nucleases and homologous recombination-independent specific insertion using Cas9.

[0145] Manipulated CAR T cells have applications in immuno-oncology. For example, CARs can be selected to target specific tumor antigens. An example of cancer that can be effectively targeted using CAR T cells is hematological cancer. In some embodiments, CAR T cell therapy can be used to treat solid tumors.

[0146] gene editing The terms “gene editing” or “genome editing,” as used herein, refer to a type of genetic manipulation in which DNA is inserted into, replaced in, or removed from a genome using artificially engineered nucleases or “molecular scissors.” This is a useful tool for elucidating the function and effects of sequence-specific genes or proteins, or for modifying cellular behavior (for example, for therapeutic purposes).

[0147] Currently available genome editing tools include zinc finger nucleases (ZFNs) and transcription activator-like effector nucleases (TALENs) for inserting genes into safe harbor loci (e.g., the adeno-associated virus integration site 1 (AAVS1) safe harbor locus). The DICE (Dual Integrase Cassette Exchange) system, utilizing phiC31 integrase and Bxb1 integrase, is a tool for targeted insertion. Additionally, clustered, regularly arranged short palindromic repeats / Cas9 (CRISPR / Cas9) techniques can be used for targeted gene insertion.

[0148] Site-directed gene editing approaches may include homology-dependent or homology-independent mechanisms.

[0149] All methods known in the art for targeted insertion of gene sequences are contemplated in the manner described herein for inserting constructs into safe harbor loci.

[0150] Crispr-Cas gene editing One effective example of gene editing is the Crispr-Cas approach (e.g., Crispr-Cas9). This approach incorporates the use of a guide polynucleotide (e.g., guide ribonucleic acid or gRNA) and a Cas endonuclease (e.g., Cas9 endonuclease).

[0151] As used herein, a polypeptide referred to as “Cas endonuclease” or having “Cas endonuclease activity” refers to a CRISPR-associated (Cas) polypeptide encoded by the Cas gene, where the Cas polypeptide is a target DNA sequence that can be cleaved when operably linked to one or more guide polynucleotides (see, for example, U.S. Patent No. 8,697,359). This definition also includes variants of Cas endonuclease that retain guide polynucleotide-dependent endonuclease activity. The Cas endonuclease used in the donor DNA insertion methods detailed herein is an endonuclease that introduces a double-strand break into DNA at a target site (e.g., within a target locus or a safe harbor site).

[0152] As used herein, the term “guide polynucleotide” refers to a polynucleotide sequence that can be complexed with a Cas endonuclease, enabling the Cas endonuclease to recognize and cleave a DNA target site. A guide polynucleotide may be a single molecule or a double molecule. A guide polynucleotide sequence may be an RNA sequence, a DNA sequence, or a combination thereof (RNA-DNA combination sequence). A guide polynucleotide consisting solely of ribonucleic acid is also referred to as “guide RNA.” In some embodiments, a polynucleotide donor construct is inserted into a safe harbor locus using a guide RNA (gRNA) in combination with a Cas endonuclease (e.g., Cas9 endonuclease).

[0153] A guide polynucleotide comprises a first nucleotide sequence domain (also called a variable targeting domain or VT domain) that is complementary to the nucleotide sequence in the target DNA, and a second nucleotide that interacts with the Cas endonuclease polypeptide. It may be a bimolecule (also called a double-stranded guide polynucleotide) containing a sequence domain (also called a Cas endonuclease recognition domain or CER domain). The CER domain of this bimolecule guide polynucleotide contains two distinct molecules that hybridize along the complementary region. The two distinct molecules may be an RNA sequence, a DNA sequence, and / or an RNA-DNA combination sequence.

[0154] Genome editing using the CRISPR-Cas approach relies on the repair of site-directed DNA double-strand breaks (DSBs) induced by RNA-induced Cas endonucleases (e.g., Cas9 endonuclease). Homologous recombination repair (HDR) of these DSBs enables precise editing of the genome by introducing defined genomic alterations, including base substitutions, sequence insertions, and deletions. Conventional HDR-based CRISPR / Cas9 genome editing involves transfecting cells with Cas9, gRNA, and donor DNA containing homologous arms matching the locus of interest.

[0155] HITI (homology-independent targeted insertion) uses a non-homologous end junction (NHEJ)-based homology-independent strategy, and this method may be more efficient than HDR. A guide RNA (gRNA) targets the insertion site. For HITI, the donor plasmid lacks homology arms, and DSB repair does not occur via the HDR pathway. The donor polynucleotide construct can be engineered to include one or more Cas9 cleavage sites adjacent to the gene or sequence to be inserted. This results in Cas9 cleavage in both the donor plasmid and the genomic target sequence. Both the target and donor have blunt ends, and a linearized donor DNA plasmid is used by the NHEJ pathway, which results in integration into the genomic DSB site. (For example, see Suzuki, K., et al. (2016). In vivo genome editing via CRISPR / Cas9 mediated homology-independent targeted integration. Nature, 540(7631), 144-149 (this related disclosure is incorporated in its entirety herein)).

[0156] Methods for performing gene editing using the CRISPR-Cas approach are known to those skilled in the art. (See, for example, U.S. applications US16 / 312,676, US15 / 303,722, and US15 / 628,533, the disclosures of which are incorporated herein by reference in their entirety). In addition, the use of endonucleases for inserting transgenes into safe harbor loci is described, for example, in U.S. application 13 / 036,343 (the disclosure of which is incorporated herein by reference in its entirety).

[0157] Guide RNA and / or mRNA (or DNA) encoding an endonuclease may be chemically linked to one or more moieties or conjugates that enhance the activity, cell distribution, or cell uptake of the oligonucleotide. Non-limiting examples of such moieties include cholesterol moieties, cholic acid, thioethers, thiocholesterol, aliphatic chains (e.g., dodecanediol or undecyl residues), phospholipids, such as dihexadecyl-rac-glycerol or triethylammonium 1,2-di-O-hexadecyl-rac-3-H-phosphonate, polyamine or polyethylene glycol chains, adamantane acetate, palmityl moieties, and lipid moieties such as octadecylamine or hexylamino-carbonyl-t-oxycholesterol moieties. See, for example, U.S. Patent Application No. 15 / 715,068 (this disclosure is incorporated herein by reference in its entirety).

[0158] therapeutic use For therapeutic purposes, manipulated cells, populations thereof, or compositions thereof are administered in effective doses to subjects, generally mammals, generally humans.

[0159] The manipulated cells may be administered to a subject by injection (e.g., by continuous injection over a period of time) or by other modes of administration known to those skilled in the art.

[0160] The manipulated cells described herein can be administered as part of a pharmaceutical composition. In some embodiments, the Disclosure provides a composition comprising the guide RNA of the Disclosure. The pharmaceutical composition may comprise one or more pharmaceutical excipients. Any suitable pharmaceutical excipient may be used, and those skilled in the art can select suitable pharmaceutical excipients. Accordingly, the pharmaceutical excipients described below are illustrative and not limiting. Additional pharmaceutical excipients include, for example, those described in Handbook of Pharmaceutical Excipients, Rowe et al. (Eds.) 6th Ed. (2009) (which is incorporated in its entirety by reference).

[0161] The manipulated cells described herein have been found to have non-pharmaceutical uses, such as the production of animal models and recombinant cell lines that express the target protein, in addition to their use in gene therapy.

[0162] The manipulated cells in this disclosure may be any cell, generally mammalian cells, and generally human cells modified by incorporating a transgene into a safe harbor locus as described herein. In some embodiments, the manipulated cells are immune cells. In some embodiments, the manipulated cells are lymphocytes. In some embodiments, the manipulated cells are T cells or T cell precursors.

[0163] The manipulated cells, compositions, and methods described herein are useful for therapeutic applications such as CAR T cell therapy and TCR T cell therapy. In some embodiments, insertion of a sequence encoding a transgene within a safe harbor locus maintains TCR expression compared to cases without insertion, enabling transgene expression while maintaining TCR function.

[0164] Various diseases treated with manipulated cells, populations thereof, or compositions thereof are provided herein. Non-limiting examples of such diseases include alopecia areata, autoimmune hemolytic anemia, autoimmune hepatitis, cancer, dermatomyositis, diabetes mellitus (type 1), certain juvenile idiopathic arthritis, glomerulonephritis, Graves' disease, Guillain-Barré syndrome, idiopathic thrombocytopenic purpura, myasthenia gravis, certain myocarditis, multiple sclerosis, pemphigus / bullous pemphigoid, pernicious anemia, polyarteritis nodosa, polymyositis, primary biliary cirrhosis. Examples of conditions that may be treated include cirrhosis, psoriasis, rheumatoid arthritis, scleroderma / systemic sclerosis, Sjögren's syndrome, systemic lupus erythematosus, certain types of thyroiditis, certain types of uveitis, vitiligo, polyangiitis (Wegener), autoimmune diseases (including, but not limited to, granulomatous diseases), hematopoietic malignancies (including, but not limited to, acute and chronic leukemia, lymphoma, multiple myeloma, and myelodysplastic syndromes), tumors of the prostate, breast, lung, colon, uterus, skin, liver, bone, pancreas, ovaries, testes, bladder, kidneys, heart, head, neck, stomach, cervix, rectum, pharynx, or esophagus solid tumors, HIV (human immunodeficiency virus)-related disorders, RSV (respiratory polynuclear virus)-related disorders, EBV (Epstein-Barr virus)-related disorders, CMV (cytomegalovirus)-related disorders, and infectious diseases (including, but not limited to, adenovirus-related disorders and BK polyomavirus-related disorders).

[0165] Cancers that can be treated with the manipulated cells (e.g., CAR T cells), populations thereof, or compositions thereof of the Disclosure include hematological cancers. In some embodiments, the cancers treated with the manipulated cells (e.g., CAR T cells), populations thereof, or compositions thereof described herein are hematological malignancies or leukemias. In some embodiments, the manipulated cells (e.g., CAR T cells), populations thereof, or compositions thereof described herein are used for the treatment of acute lymphoblastic leukemia (ALL) or diffuse large B-cell lymphoma (DLBCL). In some embodiments, the cancers are acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), myelodysplasia, myelodysplastic syndromes, acute T-lymphoblastic leukemia or acute promyelocytic leukemia, chronic myelomonocytic leukemia, or myeloacute transformation of chronic myeloid leukemia. Examples of cancers treatable using the manipulated cells described herein (e.g., CAR T cells) include, but are not limited to, breast cancer, ovarian cancer, esophageal cancer, bladder cancer or gastric cancer, salivary duct cancer, adenocarcinoma of the lung, or uterine cancer such as serous endometrial cancer. In some other embodiments, the cancer is brain cancer, breast cancer, cervical cancer, colon cancer, colorectal cancer, endometrial cancer, esophageal cancer, leukemia, lung cancer, liver cancer, melanoma, ovarian cancer, pancreatic cancer, rectal cancer, kidney cancer, gastric cancer, testicular cancer, or uterine cancer.In further embodiments, cancer may include squamous cell carcinoma, adenocarcinoma, small cell carcinoma, melanoma, neuroblastoma, sarcoma (e.g., angiosarcoma or chondrosarcoma), laryngeal cancer, parotid gland cancer, biliary tract cancer, thyroid cancer, acral lentiginous melanoma, actinic keratosis, acute lymphoblastic leukemia, acute myeloid leukemia, adenoid cystic carcinoma, adenoma, adenosarcoma, adenosquamous cell carcinoma, anal canal cancer, anal cancer, anorectal cancer, astrocytic tumor, Bartholin's gland cancer, basal cell carcinoma, bile duct cancer, bone cancer, bone marrow cancer, bronchial cancer, bronchial adenocarcinoma, carcinoid, cholangiocarcinoma, chondrosarcoma, choroid plexus papilloma / cancer Cancer, chronic lymphocytic leukemia, chronic myeloid leukemia, clear cell carcinoma, connective tissue carcinoma, cystadenoma, gastrointestinal cancer, duodenal cancer, endocrine cancer, yolk sac tumor, endometrial hyperplasia, endometrial stromal sarcoma, endometrioid adenocarcinoma, endothelial cell carcinoma, ependymal carcinoma, epithelial cell carcinoma, Ewing's sarcoma, ocular and orbital cancer, female genital cancer, focal nodular hyperplasia, gallbladder cancer, gastric pyloric cancer, gastric fundus cancer, gastrinoma, glioblastoma, glucagonoma, cardiac cancer, hemangioblastoma, hemangioendothelioma, hemangioma, hepatic adenoma, hepatic adenomatosis, hepatobiliary tract cancer, hepatocellular carcinoma, Hodgkin's disease, ileal cancer, insulino Carcinoma, carcinoma in situ, interepithelial squamous cell carcinoma, intrahepatic cholangiocarcinoma, invasive squamous cell carcinoma, jejunal cancer, joint cancer, Kaposi's sarcoma, pelvic cancer, large cell carcinoma, colorectal cancer, leiomyosarcoma, melanoma originating from lentigo malignant, lymphoma, male genital cancer, malignant mesothelioma, malignant mesothelioma, medulloblastoma, medullary epithelioma, meningeal carcinoma, mesothelioma, metastatic carcinoma, oral cancer, mucoepidermoid carcinoma, multiple myeloma, muscle cancer, nasal cavity cancer, nervous system cancer, neuroepithelial adenocarcinoma, nodular melanoma, nonepithelial skin cancer, non-Hodgkin lymphoma, oat cell carcinoma, oligodendroglia, oral cancer, osteosarcoma, papillary serous adenocarcinoma, penile Cancer, pharyngeal cancer, pituitary tumor, plasmacytoma, pseudosarcoma, pulmonary blastoma, rectal cancer, renal cell carcinoma, respiratory cancer, retinoblastoma, rhabdomyosarcoma, sarcoma, serous carcinoma, paranasal sinus cancer, skin cancer, small cell carcinoma, small intestine cancer, leiomyocyte carcinoma, soft tissue carcinoma, somatostatin-secreting tumor, spinal cancer, squamous cell carcinoma, rhabdomyosarcoma, submesothelial carcinoma, superficial spreading melanoma, T-cell leukemia, tongue cancer, undifferentiated carcinoma, ureteral cancer, urethral cancer, bladder cancer, urinary tract cancer, cervical cancer, endometrial cancer, uveal melanoma, vaginal cancer, verrucous carcinoma, vipomas, vulvar cancer, well-differentiated carcinoma, or Wilms' tumor.

[0166] In some embodiments, this disclosure provides a method for treating a subject in need of treatment by administering a composition comprising any of the manipulated cells described herein to the subject. Where used, the terms “treat,” “cure,” etc., generally refer to obtaining a desired pharmacological and / or physiological effect. This effect is prophylactic in the sense of complete or partial prevention of disease, and / or therapeutic in the sense of partial or complete cure of the disease and / or adverse effects resulting from the disease. As used herein, the term “cure” encompasses any treatment of a disease in a subject (e.g., a mammal, e.g., a human). Treatment may also refer to the administration of the manipulated cells described herein to a subject susceptible to disease but not yet diagnosed with it, including preventing the onset of the disease, inhibiting the progression of the disease, or reducing the disease (i.e., causing disease regression). Furthermore, treatment may stabilize or reduce undesirable clinical symptoms in a subject (e.g., a patient). The cell populations described herein, or compositions thereof, may be administered before, during, or after the onset of a disease or injury.

[0167] In certain embodiments, the subject has a disease, condition, and / or injury that can be treated and / or improved by cell therapy. In some embodiments, the subject requiring cell therapy is a subject having an injury, disease, or condition that thereby triggers cell therapy (e.g., therapy in which cellular material is administered to the subject). However, the intent is that it is possible to treat, improve, and / or reduce the severity of at least one symptom associated with the injury, disease, or condition. In certain embodiments, subjects requiring cell therapy include, but are not limited to, candidates for bone marrow or stem cell transplantation, subjects who have undergone chemotherapy or radiotherapy, hyperproliferative disorders or cancer (e.g., hematopoietic system), subjects who have or are at risk of developing hyperproliferative disorders or cancer, tumors (e.g., solid tumors), viral infections or subjects who have or are at risk of developing viruses. It is also intended to include subjects who have or are at risk of developing infection-related diseases.

[0168] In some embodiments, the Disclosure provides compositions of the Disclosure together with instructions for use. The instructions for use may be present in the kit as an accompanying document, on the label of the kit or its component containers, or in digital format (e.g., on a CD-ROM, via an internet link). The kit may contain one or more of the following: genome-targeted nucleic acids, polynucleotides encoding genome-targeted nucleic acids, site-specific polypeptides, and / or polynucleotides encoding site-specific polypeptides. Additional components in the kit, such as buffers (e.g., reconstituted buffers, stabilizing buffers, dilution buffers), and / or one or more control vectors are also intended.

[0169] Combination therapy In some embodiments, the manipulated cells or compositions thereof described herein are administered together with at least one additional therapeutic agent. Any suitable additional therapeutic agent may be administered together with the manipulated cells, populations thereof, or compositions thereof as described herein. In some embodiments, the additional therapeutic agent is selected from radioactive agents, ophthalmic agents, cytotoxic agents, chemotherapeutic agents, cell division inhibitors, antihormone agents, immunostimulants, anti-angiogenic agents, and combinations thereof.

[0170] In some embodiments, the manipulated cells or compositions thereof are administered together with steroids. Steroid administration can prevent or reduce the risk to subjects receiving the manipulated cells or compositions thereof who have an autoimmune response.

[0171] Additional therapeutic agents may be administered by any suitable means. In some embodiments, the manipulated cells, populations thereof, or compositions thereof described herein, and the additional therapeutic agents are administered in the same pharmaceutical composition, for example, by infusion. In some embodiments, the manipulated cells and additional therapeutic agents described herein are contained in different pharmaceutical compositions.

[0172] A pharmaceutical composition may contain one or more pharmaceutical excipients. Any suitable pharmaceutical excipient may be used, and those skilled in the art can select a suitable pharmaceutical excipient. Therefore, the pharmaceutical excipients listed below are illustrative and not limiting. Additional pharmaceutical excipients include, for example, those listed in Handbook of Pharmaceutical Excipients, Rowe et al. (Eds.) 6th Ed. (2009) (which is incorporated in its entirety by reference).

[0173] Various modes of administration of additional therapeutic agents are considered herein. In some embodiments, the additional therapeutic agent is administered by any preferred mode of administration. Generally, but not limited to, modes of administration include intravitreous, subretinal, suprachoroidal, intra-arterial, intradermal, intramuscular, intraperitoneal, intravenous, nasal, parenteral, topical, pulmonary, and subcutaneous routes.

[0174] In embodiments in which the manipulated cells and additional therapeutic agents described herein are included in different pharmaceutical compositions, the administration of the manipulated cells described herein may be performed before, simultaneously with, and / or subsequently to the administration of the additional therapeutic agents.

[0175] Further Embodiments In some embodiments, the Specified Description of an engineered cell comprising at least one sequence encoding a transgene, wherein at least one sequence is inserted into a safe harbor locus, and the safe harbor locus is located at chr10:33130000~33140000, chr10:72290000~72300000, chr11:128340000~128350000, chr11:65425000~65427000 (NEAT1), chr15:92830000~92840000, chr16:11220000~11230000, chr2:87460000~87470000, chr3:186510 The present invention provides manipulated cells located at one or more sgRNA target loci selected from 000~186520000, chr3:59450000~59460000, chr8:127980000~128000000, chr9:7970000~7980000, APRT, B2M, CAPNS1, CBLB, CD2, CD3E, CD3G, CD5, EDF1, FTL, PTEN, PTPN2, PTPN6, PTPRC, PTPRCAP, RPS23, RTRAF, SERF2, SLC38A1, SMAD2, SOCS1, SRP14, SRSF9, SUB1, TET2, TIGIT, TRAC, and TRIM28.

[0176] In some embodiments, the expression of at least one sequence encoding the transgene is operably linked to an endogenous promoter.

[0177] In some embodiments, the expression of at least one sequence encoding the transgene is operably linked to an exogenous promoter.

[0178] In some embodiments, the target loci are chr10:33130000~33140000, chr10:72290000~72300000, chr11:128340000~128350000, chr11:65425000~65427000 (NEAT1), chr15:92830000~92840000 The following ranges are selected: chr16:11220000~11230000, chr2:87460000~87470000, chr3:186510000~186520000, chr3:59450000~59460000, chr8:127980000~128000000, and chr9:7970000~7980000.

[0179] In some embodiments, the target locus is chr11:128340000~128350000 or chr15:92830000~92840000.

[0180] In some embodiments, the target locus is a gene selected from APRT, B2M, CAPNS1, CBLB, CD2, CD3E, CD3G, CD5, EDF1, FTL, PTEN, PTPN2, PTPN6, PTPRC, PTPRCAP, RPS23, RTRAF, SERF2, SLC38A1, SMAD2, SOCS1, SRP14, SRSF9, SUB1, TET2, TIGIT, TRAC, and TRIM28.

[0181] In some embodiments, the safe harbor locus is the GS94 or GS102 integration site shown in Table 4.

[0182] In some embodiments, the exogenous promoter is the EF1a promoter.

[0183] In some embodiments, the manipulated cells are natural killer (NK) cells, induced pluripotent stem cells (iPSCs), human pluripotent stem cells (HSPCs), T cells, or T cell precursors.

[0184] In some embodiments, the transgene encodes a recombinant protein, a therapeutic agent, or a chimeric antigen receptor (CAR).

[0185] In some embodiments, compositions comprising the manipulated cells and pharmaceutical excipients described herein are provided.

[0186] In some embodiments, this specification provides guide ribonucleic acid (gRNA) for editing cells at the safe harbor locus, wherein the gRNA comprises one of sequence numbers 1 to 120.

[0187] In some embodiments, this specification provides a method for editing a cell having chromosomal DNA, comprising inserting at least one sequence encoding a transgene into a safe harbor locus of the cell's chromosomal DNA, where the safe harbor locus is chr10:33130000~33140000, chr10:72290000~72300000, chr11:128340000~128350000, chr11:65425000~65427000 (NEAT1), chr15:92830000~92840000, chr16:11220000~11230000, chr2:87460000~87470000, chr The method provides a target sgRNA locus located at one or more of the following loci selected from 3:186510000~186520000, chr3:59450000~59460000, chr8:127980000~128000000, chr9:7970000~7980000, APRT, B2M, CAPNS1, CBLB, CD2, CD3E, CD3G, CD5, EDF1, FTL, PTEN, PTPN2, PTPN6, PTPRC, PTPRCAP, RPS23, RTRAF, SERF2, SLC38A1, SMAD2, SOCS1, SRP14, SRSF9, SUB1, TET2, TIGIT, TRAC, and TRIM28.

[0188] In some embodiments, the target loci are chr10:33130000~33140000, chr10:72290000~72300000, chr11:128340000~128350000, chr11:65425000~65427000 (NEAT1), chr15:92830000~92840000 The following ranges are selected: chr16:11220000~11230000, chr2:87460000~87470000, chr3:186510000~186520000, chr3:59450000~59460000, chr8:127980000~128000000, and chr9:7970000~7980000.

[0189] In some embodiments, the target locus is chr11:128340000~128350000 or chr15:92830000~92840000.

[0190] In some embodiments, the target locus is a gene selected from APRT, B2M, CAPNS1, CBLB, CD2, CD3E, CD3G, CD5, EDF1, FTL, PTEN, PTPN2, PTPN6, PTPRC, PTPRCAP, RPS23, RTRAF, SERF2, SLC38A1, SMAD2, SOCS1, SRP14, SRSF9, SUB1, TET2, TIGIT, TRAC, and TRIM28.

[0191] In some embodiments, the transgene encodes a recombinant protein, a therapeutic agent, or a chimeric antigen receptor (CAR).

[0192] In some embodiments, at least one sequence includes an exogenous promoter, which is operably ligated to the transgene.

[0193] In some embodiments, the cells are T cells or T cell precursors.

[0194] In some embodiments, at least one sequence is inserted using homologous recombination repair or homologous recombination-independent specific insertion.

[0195] In some embodiments, at least one sequence is inserted using one or more guide ribonucleic acids (gRNAs) and one or more Cas9 endonucleases, wherein one or more gRNAs include one of sequence numbers 1 to 120.

[0196] In some embodiments, this specification provides an ex vivo method for obtaining manipulated cells or populations thereof, comprising: obtaining cells; and genetically modifying the cells by inserting at least one sequence encoding a transgene into a safe harbor locus, wherein the safe harbor locus is chr10:33130000~33140000, chr10:72290000~72300000, chr11:128340000~128350000, chr11:65425000~65427000 (NEAT1), chr15:92830000~92840000, chr16:11220000~11230000, chr2:87460000~8747 The present invention provides an ex vivo method for targeting one or more sgRNA target loci selected from 0000, chr3:186510000~186520000, chr3:59450000~59460000, chr8:127980000~128000000, chr9:7970000~7980000, APRT, B2M, CAPNS1, CBLB, CD2, CD3E, CD3G, CD5, EDF1, FTL, PTEN, PTPN2, PTPN6, PTPRC, PTPRCAP, RPS23, RTRAF, SERF2, SLC38A1, SMAD2, SOCS1, SRP14, SRSF9, SUB1, TET2, TIGIT, TRAC, and TRIM28.

[0197] In some embodiments, obtaining cells includes (i) collecting a tissue sample from a subject, (ii) isolating cells from the tissue sample, and (iii) culturing the cells in vitro.

[0198] In some embodiments, the cells are stem cells, natural killer (NK) cells, induced pluripotent stem cells (iPSCs), human pluripotent stem cells (HSPCs), T cells, or T cell precursors.

[0199] In some embodiments, at least one sequence is inserted using homologous recombination repair or homologous recombination-independent specific insertion.

[0200] In some embodiments, the gene modification in step (b) comprises contacting a cell with one or more guide ribonucleic acids (gRNAs), at least one sequence, and one or more Cas9 endonucleases, wherein the one or more gRNAs and Cas9 endonucleases facilitate the insertion of at least one sequence into chromosomal DNA within a safe harbor locus, and the one or more gRNAs comprise one of sequence numbers 1 to 120.

[0201] In some embodiments, at least one sequence includes an exogenous promoter, which is operably ligated to the transgene.

[0202] In some embodiments, this specification provides a method for treating a subject who has or is at risk of having a disease, comprising administering to the subject an effective amount of the manipulated cells described herein.

[0203] In some embodiments, this specification provides a method for treating a subject who has or is at risk of having a disease, the method comprising carrying out the method described herein and administering to the subject a composition comprising an effective amount of cells or populations thereof.

[0204] In some embodiments, the disease is cancer. [Examples]

[0205] The following are examples of methods and compositions of the present invention. Considering the general description herein, it will be understood that various other embodiments may be implemented.

[0206] The following are examples of specific embodiments for carrying out the present invention. The examples are provided for illustrative purposes only and are not intended in any way to limit the scope of the present invention. Although efforts have been made to ensure accuracy with respect to the numerical values ​​used (e.g., quantities, temperatures, etc.), some experimental error and deviation should naturally be permitted.

[0207] Unless otherwise indicated, the practice of this invention will utilize conventional methods of protein chemistry, biochemistry, recombinant DNA techniques, and pharmacology, within the scope of the skills of the art. Such techniques are well described in the literature. See, for example, TECreighton, Proteins: Structures and Molecular Properties (WH Freeman and Company, 1993), ALLehninger, Biochemistry (Worth Publishers, Inc., current addition), Sambrook, et al., Molecular Cloning: A Laboratory Manual (2nd Edition, 1989), Methods In Enzymology (S. Colowick and N. Kaplan eds., Academic Press, Inc.), and Remington's Pharmaceutical Sciences, 18th Edition (Easton, Pennsylvania: Mack Publishing Company, 1990).

[0208] Example 1: Identification of knock-in gene loci in the coding region The objective of the experiments in this series of examples was to identify T cell knock-in (KI) loci in coding regions other than the T cell receptor alpha constant (TRAC) locus. The criteria and requirements shown in Table 1 were used to select candidate loci. TIFF2023547887000002.tif194165

[0209] Generally, the requirements for candidate KI loci within the coding region were that the coding gene was either not essential for T cell function, or that knockout of the gene was beneficial for chimeric antigen receptor therapy (CAR T) function.

[0210] As shown in Table 1, for comparative purposes, some of the data used to identify candidate KI loci were partially derived from Roth, TL, et al. 2019 (Rapid discovery of synthetic DNA sequences to rewrite endogenous T cell circuits. bioRxiv, 604561), and this relevant disclosure is incorporated herein by reference in its entirety. A summary of the data from Roth, TL, et al.'s paper is shown in Figure 3.

[0211] Figures 4A and 4B show the processed RNA-seq data, demonstrating that the samples clustered based on their activation state and cell type. Donor 4 (AKI4) clustered differently from the other donors and was identified as an outlier, excluded from the rest of the analysis. Transcript expression data from RNA-seq experiments of 90 genes cited in Roth, TL et al. correlated with the transcription expression data in Roth, TL et al.'s paper (see Figures 5A and 5B).

[0212] Figure 6 shows process ATAC-seq data focusing on the 10kb region around the transcription start site (TSS). Again, Donor 4 (AKI4) was identified as an outlier based on its expression profile in both CD4 and CD8 cells and was excluded from the rest of the analysis. The results of the remaining ATAC-seq analysis are shown in Figures 7A–8. The data in Figure 7A for the TSS enhancement score also showed that all libraries were of high quality. Data on the open chromatin region around the TRAC locus revealed the highest signal near exon 3 rather than exon 1 (Figure 8).

[0213] Determining knock-in efficiency: Figures 9 and 10 show the KI efficiency results (obtained using the model described below) from the paper by Roth, TL et al., based on five donors, two gRNAs, and two replicate / gRNAs.

[0214] A linear model was constructed to estimate the KI efficiency of approximately 90 genes using RNA-seq and ATAC-seq data. The linear model captured 33% of the variability in the data (i.e., R 2 (=0.33). Figure 11 shows the KI efficiency for RNA-seq data on day 2 (d2), RNA-seq data on day 4 (d4), and ATAC data on day 2. A linear model was applied to the remaining candidate genes to estimate their KI efficiency.

[0215] Candidate coding loci were selected by first ranking all genes in a pooled dataset by their predicted KI efficiency using RNA-seq expression data on day 2 (d2). Candidate coding loci needed to be stably expressed during T cell activation (e.g., ≤2x expression change compared to day 0 (d0)). Candidate loci also had to be accessible based on ATAC-seq data. Using this selection process / requirements, 16 well-characterized coding genes (with known functions) were selected as candidate genes. These 16 knockouts would confine the function of CAR T cells (e.g., B2M, CD5, SMAD2, PTPRC, CD3E). An additional 12 coding genes with high predicted KI efficiency and no apparent essential functions (inactive coding genes) were selected as candidate genes (see Table 2). TIFF2023547887000003.tif136165

[0216] Example 2: Identification of knock-in gene loci in gene deserts Table 3 summarizes the criteria for selecting candidate loci in non-coding regions or gene deserts. TIFF2023547887000004.tif157165

[0217] To select candidate regions within the non-coding region, the inventors began by examining the highly accessible regions of the genome (a 10kb window). The most accessible regions overlapped with (i) annotated protein-coding genes (>50% of the accessible region), (ii) pseudogenes and non-coding RNAs (approximately 20% of the accessible region), and (iii) enhancer / regulatory regions (approximately 20% of the accessible region). Candidate genes needed to be <10kb from the coding region. Several regions that overlapped with long intergene non-coding RNAs (lincRNAs) but did not have a clear function in T cells were also considered.

[0218] Examples of other criteria used in the art for the selection of SHS are, for example, Pellenz, S., et al. (2019). New human chromosomal sites with “safe harbor” potential for targeted transgene insertion. Human Gene Therapy, 30(7), 814-828 (this related disclosure is incorporated herein by reference in its entirety).

[0219] Figure 12 is a plot showing normalized ATAQ SEQ data for top candidate non-coding regions.

[0220] Using the selection process / requirements described above, 11 candidate regions were selected in the gene desert. In total, there were 39 candidate KI loci, including coding and non-coding regions that were evaluated as safe harbor loci (predicted loci).

[0221] Example 3: Experimental evaluation of predicted gene loci material ●120 types of sgRNAs were ordered from Synthego (3 sgRNAs per region), and their editing efficiency was evaluated by next-generation sequencing (NGS). ■ 87 types of target coding genes ■33 Target Gene Deserts ● 189 constructs were synthesized by Genscript ■ Homologous arms: 450 bp each ■ eGFP was used as a reporter ■ Vector backbone: pUC57-Kan backbone ■ 78 has an endogenous promoter ■ 111 has an EF1a-HTLV promoter ● The constructs were sequence-verified by Genscript and most were internally verified by sequencing. The sgRNA sequences are listed in Table 4 and the construct sequences are listed in Table 5.

[0222] Methods

[0223] To evaluate the effectiveness of the predicted loci, the following were used:

[0224] (87 endogenous constructs + 120 exogenous constructs) * 2 = 414 wells + controls = 460

[0225] Three time points: week 1 (d6 = day 6), week 3 (d21 = day 21), and week 4 (d28 = day 28) for 3 donors, 2 replicates

[0226] Controls

[0227] DNA only (no ribonucleoprotein (RNP)): episomal expression (n = 8)

[0228] DNA + non-targeting guide + RNP: to confirm whether DNA delivery is more efficient with RNP (n = 8)

[0229] pMax GFP was measured to confirm that transfection was good (n = 3).

[0230] WT cells without electroporation

[0231] WT cells with electroporation

[0232] The controls were dispersed throughout the plate.

[0233] Cells were electroporated without RNP / HDR to confirm whether the cell counts were meaningful.

[0234] Two additional donors were added and changed to three replicates at one time point: week 1 (d6).

[0235] FACS panel: GFP, TCR, Zombie

[0236] Wash every three wells.

[0237] The secondary data collected includes the following: RNA-seq data: at d0, d2, and d4 (to determine stable expression), ATAC-seq data: at d2 (to identify activated cells). The methods used to perform the RNA-seq and ATAC-seq experiments are in Roth, T.L., et al. 2019. (Rapid discovery of synthetic DNA sequences to rewrite endogenous T cell circuits. bioRxiv, 604561 (incorporated herein by reference in its entirety).

[0238] .Auto-gating was performed on the FACS data using.fcs files. For constructs with endogenous promoters, all five donors and all three time points were used. For constructs with the EF1a promoter, three donors (donors 1-3) and two time points (week 3 and week 4) were used.

[0239] To summarize the data, wells with KI efficiency% (GFP high cells%) ≤ 10% (presumably gating errors, experimental errors, or minimal integration) were excluded. Then, the Loci were ranked by the median expression between donors and the median KI efficiency% between donors. [[ID=3)]

[0240] The significance of the gene loci was calculated using robust rank aggregation, a methodology used for consistent ranking of gene loci across donors and time points. Methods for performing robust rank aggregation are known in the art. (See, for example, Kolde, R., et al. (2012). Robust rank aggregation for gene list integration and meta-analysis. Bioinformatics (Oxford, England), 28(4), 573-580 (its disclosure is incorporated herein by reference in its entirety)).

[0241] result

[0242] The results of the analysis of the control and experimental groups are shown in Figures 13A to 1325.

[0243] The results of the pmax_GFP control experiment revealed that donor 5 had significantly higher cell counts than the other donors. Generally, the GFP_high readings decreased over time as expected (Figures 13A and 13B).

[0244] Experiments analyzing untargeted controls for changes in episomal GFP expression revealed that episomal GFP expression decreased to less than 0.05 over time (Figures 14A and 14B). Some outliers were attributed to gating errors, which were most severe in donor 3. The WT-controlled experiments also showed GFP_high readings of <0.05, as expected (Figure 15).

[0245] As shown in Figures 16 and 17, using sgRNA5 to target the B2M safe harbor locus resulted in a more consistent trend among donors.

[0246] Comparison of the GFP expression trends between sgRNA79 and sgRNA83 for TRAC insertion and expression using an endogenous reporter revealed that the trend for donor 2 was different between sgRNA79 and sgRNA83, while the trend for donor 4 was the same (Figures 18 and 22). Some potential reasons for the variations observed between replicates and donors include the following:

[0247] (1) Manual handling of a large number of plates (e.g., Figure 26):

[0248] Edge effect

[0249] Electroporation error

[0250] (2) Intrinsic differences between donors (e.g., Figure 27):

[0251] There were consistent differences in the throughput of certain wells of the assay (over several weeks)

[0252] The number of cells was different between donors

[0253] (3) Gating error (e.g., Figure 28):

[0254] One peak vs. >2 peaks in the GFP signal

[0255] Example 4: Ranking of loci by expression and KI efficiency Loci were ranked based on the reporter gene, GFP, and the mean fluorescence intensity (MFI) of the KI efficiency.

[0256] Figure 29 shows the GFP MFI and KI efficiencies of all key loci with endogenous promoters. The B2M locus reported the highest GFP MFI. The TRAC locus was among the top 10 MFIs. The highest GFP MFI readings were reported at week 1 and decreased slightly at weeks 3 and 4. The results also showed that most top loci had more than 1 sgRNA. Regarding KI efficiency, the SOCS1 locus reported the highest KI efficiency. Overall, KI efficiency showed greater variability among donors than GFP MFI.

[0257] Figure 30 shows the GFP MFI and KI efficiencies of all key loci with exogenous promoters (e.g., EF1a promoter). The TRAC locus reported the highest GFP MFI, with comparable expression at weeks 3–4. The results also showed that most top loci had more than 1 sgRNA. Regarding KI efficiency, the SOCS1 locus reported the highest KI efficiency. Overall, KI efficiency was less variable when driven by exogenous promoters than when driven by endogenous promoters.

[0258] Figures 31A, 31B, and 31C show the GFP MFI and KI efficiencies of all key loci with endogenous and exogenous (e.g., EF1a) promoters. The results showed that expression driven by the EF1a promoter was approximately 10 times higher than that driven by the endogenous promoter (Figure 31A). Regarding KI efficiency, the SOCS1 locus reported the highest KI efficiency. At weeks 3 and 4, KI efficiency was higher when driven by the exogenous promoter than when driven by the endogenous promoter.

[0259] Example 5: Evaluation of TCR expression in candidate non-coding sites This experiment was conducted to identify target loci and integration sites that enable high transgene expression without disrupting the TCR. Several gene deserts (e.g., gene deserts 2, 3, 5, and 6) were identified as having high transgene expression (Figure 32A).

[0260] To evaluate and identify preferred knock-in sites, TCR expression was measured after knock-in of the PrimeR (Prime Receptor (Myc)) circuit cassette. Myc exhibits an N-terminal Myc epitope tag to facilitate detection of surface-expressed primer receptors. Briefly, T cells activated by CD3-CD28 Dynabead were electroporated with sgRNA / Cas9 RNPs targeting the indicated sites (see Figures 32B and 33A) and HDRT with homologous arms directed towards HDR-mediated integration to the indicated sites. Six days post-electroporation, cells were stained with anti-TCR alpha / beta and anti-myc antibodies and analyzed using an Attune NxT flow cytometer. As shown in Figure 32B, TCR expression was maintained at the GS94 and GS102 candidate integration (knock-in) sites. Only two-thirds of cells with the PrimeR circuit cassette knocked into the GS79 (TRAC) locus maintained TCR expression. These results indicated that the GS94 and GS102 sites showed better potential for TCR stimulation.

[0261] The percentage of cells showing effective knock-in (based on PrimeR measurements) was 36% ± 4% when using the GS94 integration site, compared to 32% ± 5% when using the TRAC integration site. These results highlight the GS94-containing integration site that supports a reproducible high circuit cassette knock-in rate. See Figure 33A.

[0262] Example 6: Evaluation of circuit manifestation and function of GS94 GS94 is a candidate integration site located on the distal q arm of chromosome 11. It is within 180–350 kb of the promoters of ETS1 and FLI1 (Figure 33B), but the risk of integration vector gene therapy is considered low. Circuit expression and functional potential of the GS94 gene were evaluated.

[0263] T cells underwent circuit cassette integration with PrimeR at the GS79(TRAC) and GS94 integration sites. The cells were co-cultured with K562 C19 cells for 48 hours, and then PrimeR-induced CAR MFI was compared to PrimeR MFI.

[0264] In short, the T cells generated as described in the above example were co-cultured with K562 CD19+ / MSLN- cells 7 days after electroporation. MSLN (mesothelin) is a gene overexpressed in human pancreatic cancer. The cells were then stained with anti-FLAG antibody 48 hours after the start of co-culture and analyzed on an Attune NxT flow cytometer. The results revealed that GS94 resulted in superior CAR induction with high primeR expression after 48 hours of co-culture with K562 CD19 cells. See Figure 34A. GS94 resulted in prime antigen-dependent CAR expression that was approximately twice as high as expression at several other candidate integration sites and TRAC integration sites. In addition, on average, the prime receptor surface expression level was more than 50% of the expression level when using the TRAC integration site.

[0265] Cytotoxicity and cytokine secretion To evaluate the effects of candidate integration sites on cytotoxicity and cytokine secretion, T cells integrated with PrimeR and circuit cassettes at the GS79(TRAC) and GS94 integration sites were co-cultured with K562 C19 / MSLN cells for 48 hours. MSLN is a gene overexpressed in human pancreatic cancer. Cells were treated with a 1:1 effector:target cell ratio (1:1 E:T). Briefly, the T cells generated as described above were co-cultured with K562 CD19+ / MSLN+ cells 7 days after electroporation. 48 hours after the start of co-culture, the supernatant was collected and analyzed for cytokine levels via Luminex. Cytokine measures included IL-2, INFg, and TNF. Cytotoxicity was analyzed by measuring the luciferase activity of the remaining target cells after 48 hours. In Figure 34B, each data point represents two replicates, and the line represents the range of cytotoxicity to replication. As shown in Figure 34B, the GS94 integration site resulted in superior cytotoxicity and cytokine secretion after 48 hours of co-culture with K562 C19 / MSLN cells.

[0266] Prime-independent cytotoxicity To compare the effect of candidate integration sites on cytotoxicity with prime-independent cytotoxicity, T cells integrated with PrimeR and circuit cassettes at the GS79(TRAC) and GS94 integration sites were co-cultured with K562 CD19+ / MSLN+ cells or K562 CD19- / MSLN+ cells ("K562_MSLN") for 48 hours on day 7 after electroporation. E:T cell ratios of 0.3, 1.0, and 3.0 were tested. See Figures 35A and 35B. Cytotoxicity was analyzed by measuring the luciferase activity of the remaining target cells 48 hours after the start of co-culture. As shown in Figure 35B, the GS94 integration site yielded comparable cytotoxic performance to the TRAC integration site, and there was no prime-independent cytotoxicity.

[0267] Prime-independent cytokine secretion To compare the effect of candidate integration sites on cytotoxicity with prime-independent cytotoxicity, T cells that had undergone PrimeR and circuit cassette integration at the GS79(TRAC) and GS94 integration sites generated as described above were co-cultured with K562 CD19+ / MSLN+ cells. The group with only target cells (E:T=0, targets only) was compared with the group with an E:T cell ratio of 1. After 48 hours of co-culture with K562 CD19+ / MSLN+ cells, the supernatant was collected and analyzed for cytokine levels via Luminex to measure the secretion of IL-2, INFg, and TNF cytokines. See Figures 36A and 36B. As shown in Figure 36B, the GS94 integration site resulted in equivalent cytokine secretion to the TRAC integration site, and there was no prime-independent secretion of IL-2, INFg, or TNF.

[0268] Prime-independent CAR expression To evaluate the effect of candidate integration sites on prime-independent CAR expression, T cells that received PrimeR and circuit cassette integration at the GS79(TRAC), GS94, and GS102 integration sites were cultured in vitro for 32 days. On days 5, 12, 19, and 28 of the experiment, cells were treated with repeated CD3 / CD28 stimulation. On day 16, cells were evaluated for CAR expression using a flow cytometry assay. As shown in Figure 37, T cell activation by the TCR did not result in primeR-independent CAR expression from circuit cassette integration at candidate integration sites.

[0269] The T cells generated as described above were cultured in 96-well plates, and the T cell growth medium was changed every two days. On days 5, 12, 19, and 28, the T cells were stimulated with 1:1 CD3 / CD28 Dynabeads. The cells were analyzed for PrimeR expression by myc epitope tag staining and CAR expression by FLAG epitope tag staining at the indicated time points. Flow analysis was performed on an Attune NxT flow cytometer.

[0270] Example 7: Evaluating the stability of prime receptor expression over several weeks. To evaluate the effect of candidate integration sites on stable (sustained) PrimeR expression, T cells with PrimeR and circuit cassette integration at the integration site shown in Figure 38 were cultured in vitro for 32 days. Briefly, the T cells generated as described above were cultured in 96-well plates, and the T cell growth medium was changed every two days. On days 5, 12, 19, and 28, the T cells were stimulated with repeated 1:1 CD3 / CD28 Dynabeads stimulation. Flow cytometry assays were performed on days 16 and 32 using an Attune NxT flow cytometer. Cells were analyzed for PrimeR expression by myc epitope tag staining. As shown in Figures 38A and 38B, the GS94 integration site resulted in stable PrimeR expression for at least 4 weeks.

[0271] Example 8: Evaluation of On-Target Editing Efficiency The iGUIDE-Seq assay was used to evaluate the on-target editing efficiency of candidate knock-in sites. The method used to perform the iGUIDE-Seq assay is illustrated in Figure 39A and described in Nobles et al. Genome Biology (2019) (which is incorporated herein by reference in its entirety). As shown in Figure 39B, the GS94 integration site had the highest on-target editing efficiency among the evaluated candidate integration sites. As shown in Figure 39C, GS94 did not result in the estimated off-target editing observed in both donors.

[0272] Example 9: Evaluation of GS94 knock-in method Elevation prediction: Calculation predictions of potential off-target sites from (gs94) were performed using Elevation-search (Listgarten et al. 2018. Prediction of off-target activities for the end-to-end design of CRISPR guide RNAs. Nat Biomed Engr 2, 37-48, software available from https: / / github.com / Microsoft / Elevation). All sites identified by Elevation-search were analyzed using rhAmp-seq.

[0273] Forty-nine candidate off-target sites and GS94 target sites of GS94, identified by rhAmpSeq:iGUIDE or an elevation prediction algorithm, were characterized using rhAmpSeq (Integrated DNA Technologies, Inc.). This targeted amplification enables NGS-based quantification of editing occurring simultaneously at multiple sites. Genomic DNA from T cells from at least two donors treated individually with each of the following seven guides: GS84, GS94, GS95, GS96, GS102, GS108, and GS138, was isolated using the GenFind V3 DNA purification system (Beckman Coulter). Fifty loci were covered using two separate rhAmpSeq amplification pools, and this procedure was performed for each sample as recommended by Integrated DNA Technologies. The rhAmpSeq libraries were sequenced on MiniSeq with an intermediate output kit (300 cycles) (Illumina). The CRISPResso2 algorithm (https: / / github.com / pinellolab / CRISPResso2) was used to determine the proportion of insertions and deletions at each amplified locus. Statistical significance using the chi-square test (FDR-adjusted p-value ≤ 0.001) was observed only at the GS94 site.

[0274] RNA-seq: To evaluate the changes induced by GS94 integration at the transcriptional level, the CD19 / MSLN circuit was integrated into the GS79 (TRAC), GS94, and GS102 integration sites. On day 6 post-integration, 1e6 edited cells were sorted using BD FACSAria based on transgene expression. RNA was isolated from the sorted T cells using the RNeasy kit (Qiagen). The purified RNA was converted into an NGS library using the TruSeq RNA Library Preparation Kit v2 (Illumina). The library was sequenced on either a NovaSeq6000 or NextSeq550 instrument (Illumina). The STAR 2.7.3a aligner (Dobin A. et al. Bioinformatics. 2013. 29:15-21) was used to align the RNA-seq data to the reference human GRCh38 transcriptome to obtain gene-level read counts. edgeR (Robinson MD et al. Bioinformatics. 2010. 26:139-140) was used to combine the data across both donors to calculate differential expression. The only genes within 300 Kb of the GS94 site, ETS1 and FLI1, were not differentially expressed in cells with integration at the GS94 integration site compared to cells with integration at either of the other two loci. At a FDR-adjusted p-value cutoff of 0.01, the number of differentially expressed genes was minimal (less than 100 genes across the genome).

[0275] Cytokine-independent proliferation assay: To evaluate the safety of primary T cells with GS94 locus KI, a cytokine-independent proliferation assay was performed to assess the potential for oncogenic transformation. Briefly, primary human T cells that received CD19 / MSLN circuit cassette integration at the GS94 locus were thawed and allowed to recover overnight. Then, 1×10 6 cells were seeded into one well of a 24-well-GRex plate and cultured in medium for 5 days with or without cytokines. Cell number and viability were recorded on days 0, 3, and 5. As a positive control, 1×10 6Jurkat cells were cultured in parallel in cytokine-free medium. As shown in Figure 43, GS94 KI T cells maintained good viability and total cell count when cultured with cytokines, but the viability of GS94 KI T cells dramatically decreased over 5 days when cultured without cytokines, with no viable cells remaining on day 5. Positive control Jurkat cells maintained good viability and expansion without cytokines throughout the assay. Taken together, these data indicate that GS94-edited primary human T cells are still dependent on exogenous cytokines for growth, survival, and expansion, and therefore there are no concerns about cell transformation.

[0276] result The specificity of CRISPR reagents targeting candidate loci including GS94 (e.g., SpCas9 complexed with sgRNA) was evaluated by iGUIDE-seq (Figure 40). GS94-targeted CRISPR RNPs showed the highest percentage of iGUIDE-seq oligocassette trapping events among all evaluated candidates, and control sgRNA sequences from iGUIDE-seq publications showed similar specificity to those reported in the original publications, suggesting that the assay was performed as expected.

[0277] The proposed off-target sites were obtained from the iGUIDE-seq output, which already suggested that the proposed sites were false. Additional target sites were predicted by a computational approach (Elevation software package). High-throughput sequencing libraries were prepared for each of the proposed off-target sites using rhAmp-seq, and this method was applied to DNA samples from T cells electroporated with CRISPR RNPs targeting the candidate target sites. The resulting NGS data were processed with CRISPResso2 software, and the frequency of insertions and deletions (indels) was used as an indicator of CRISPR cleavage activity, as is common in practice. T cells electroporated with GS94-targeted CRISPR RNPs showed a lower frequency of indels in the set of proposed off-target sites compared to T cells treated with CRISPR RNPs targeting other sites, which is consistent with GS94-targeted CRISPR RNPs that do not have consequent or detectable off-target activity and are therefore the most specific of the sets evaluated (Figure 41).

[0278] The potential effects of transgene integration at the GS94 site on the regulation of the T cell transcriptome were evaluated by knocking in a large cassette at the site, growing T cells for several days, selecting cells expressing the transgene within the cassette, and then collecting RNA from the cells. RNA-seq libraries were prepared, sequenced, and analysis of the resulting Illumina sequencing data revealed no biological or statistically significant differences in the expression of any gene within 300kb of the GS94 site in cells with GS94 integration compared to cells with TRAC or GS102 integration (Figure 42). Furthermore, any other differences in gene expression that reached statistical significance were minimal in number and effect size, consistent with noise in the comparison.

[0279] To evaluate whether transgene integration at GS94 can confer a transformed phenotype, cells with integration at the GS94 site were cultured in vitro with and without cytokines. Cells survived and remained viable with cytokine addition, but died and lost viability without cytokine supplementation (Figure 43). Positive control Jurkat cells remained viable and proliferated. Overall, this indicates that transgene integration at GS94 does not confer the ability for cytokine-independent growth, a characteristic of T cell transformation.

[0280] Example 10: In vivo insertion of a CAR expression cassette The in vivo efficacy of T cells possessing a transgene cassette expressing a tumor antigen-recognizing CAR, or a CAR under the control of a priming receptor that recognizes the tumor antigen near the anatomical vicinity of the tumor, will be evaluated against human tumor cells such as K562, which have been engineered to express the CAR antigen or an antigen recognized by both the priming receptor and the CAR. Tumor cells (e.g., 1e6) are injected subcutaneously into the flank of NSG mice (Jackson Laboratories). Tumor growth is assessed by caliper dimensional measurements every 2–4 days. When the tumor volume reaches approximately 100 cubic mm, the mice are intravenously injected with 5e6 T cells possessing a CAR or prime-CAR circuit cassette integrated at a specific site by CRISPR-mediated insertion, or T cells engineered with CRISPR RNP alone, or PBS alone as a placebo injection. Tumor growth is monitored, and when the tumor volume reaches 2000 cubic mm, the mice are euthanized. Peripheral blood is bled from mice via a post-orbital procedure, and the temporal expansion of engineered T cells is observed using flow cytometry and / or ddPCR. At sacrifice, the spleen, blood, tumor, and / or other tissues are analyzed for the presence of engineered T cells via flow cytometry, ddPCR, and / or immunohistochemistry. The results demonstrate that engineered T cells engineered with cassette integration at one of the defined genomic loci result in tumor regression and clearance in injected mice compared to T cells without cassette integration, demonstrating that engineered T cells are detectable in the peripheral blood and tissues of injected mice.

[0281] Example 11: Evaluation of non-viral insertion of a large 8.3kb expression cassette in GS94 Next, using the materials / methods described above, an 8.3kb insert was inserted into the GS94 safe harbor gene locus of T cells. A diagram of the cassette is shown in Figure 44.

[0282] Construct generation

[0283] To generate plasmid constructs for knock-in, synthetic DNA was ordered from Twist, IDT, and GENEWIZ and assembled via Gibson Assembly and Golden Gate Assembly. The plasmids contained homologous arms homologous to sequences adjacent to CRISPR target sites in the genome, with lengths of 1.2 kb or 450 bp.

[0284] T cell manipulation

[0285] T cells were enriched from peripheral blood mononuclear cells (PBMCs) obtained from a normal donor, Leukopak (STEMCELL Technologies), using Lymphoprep (STEMCELL Technologies) and the EasySep human T cell isolation kit (STEMCELL Technologies). Subsequently, the T cells were activated with CD3 / CD28 dynabeads (ThermoFisher, 40203D) in a 1:1 bead-to-cell ratio in TexMACS medium (Miltenyi 130-197-196) supplemented with 3% human AB serum (Gemini Bio) and 12.5 ng / ml human IL-7 and IL-15 (Miltenyi premium grade). After incubation at 37°C and 5% CO2 for 48 hours, electroporation was performed.

[0286] CRISPR RNPs were prepared by combining 120 μM of sgRNA (Synthego) targeting the DNA sequence GAGCCATGCTTGGCTTACGA (GS94, SEQ ID NO: 94), 62.5 μM of sNLS-SpCas9-sNLS (Aldevron), and P3 buffer (Lonza) in a volume ratio of 5:1:3:6, and incubated at room temperature for 15 minutes. The optimal amount of plasmid DNA (ranging from 0.5 to 3 micrograms), determined by dose titration, was mixed with 3.5 μl of RNP. T cells were counted, beads removed, centrifuged at 90 × G for 10 minutes, and resuspended in 10^6 cells / 14.5 μl of P3 with the addition of an adjuvant (Lonza). 14.5 μl of T cell suspension was added to a DNA / RNP mixture and transferred to a Lonza 384-well Nucleocuvette plate, which was pulsed using a Lonza HT Nucleofector system code EH-115. After resting the cells at room temperature for 15 minutes, they were transferred to a 96-well plate (Sarstedt) in TexMACS medium supplemented with 12.5 ng / ml human IL-7 and IL-15 (Miltenyi premium grade).

[0287] Transgene expression was detected by staining with anti-Myc antibody (Cell Signaling Technology clone 9B11) and anti-Flag antibody (RnD system, clone 1042E), and analyzed on an Attune NxT flow cytometer. Other antibodies used included LIVE / DEAD Fixable Near-IR (Thermo Fisher), TCR alpha / beta antibody (BioLegend clone IP26), CD4 antibody (BioLegend clone RPA-T4), and CD8 antibody (BioLegend clone SK1).

[0288] Priming receptor induction

[0289] To evaluate the functional activity of the transgene (i.e., the synthetic pathway), edited T cells were co-cultured with a target cell line expressing a priming antigen in a 1:1 E:T ratio and incubated for 24 hours. The T cells were harvested and stained with anti-Myc antibody and anti-Flag antibody to evaluate priming receptor and CAR expression, respectively.

[0290] To evaluate whether the integration of the 8.3kb transgene in GS94 resulted in functional knock-in, cells were cultured in parental K562 cells and K562 cells expressing the allogeneic priming antigen in a 1:1 E:T cell ratio. The cells were assayed by flow cytometry after 48 hours as described above. K562 cells with the priming antigen induced CAR expression, while control parental K562 cells did not (Figure 45). Overall, this indicates that the priming receptor induced CAR expression after insertion of the 8.3kb transgene circuit. Therefore, insertion of the 8.3kb transgene circuit resulted in the expression of multiple functional genes.

[0291] Example 12: Differentiation of edited T cells method

[0292] Two donor T cells, edited as described above using priming receptors and the CAR synthesis pathway, were phenotypically profiled using cell surface T cell subset markers by flow cytometry. Quiescent T cells were isolated from in vitro culture conditions, washed with PBS before staining with Zombie-Aqua viability dye, CD4, CD8, CD45RA, CCR7, and CD27, and analyzed with Attune NxT using FMO as a gating control. In FlowJo, single viable lymphocytes were selected by SSC and FSC, and subset profiling based on CCR7, CD27, and CD45RA combinations was used to identify naive or stem cell memory (Tn / Tscm:CD45RA+CCR7+CD27+), central memory- (Tcm:CD45RA-CCR7+CD27+), effector memory (Tem:CD45RA-CCR7-CD27-), or terminal effector (Tte:CD45RA+CCR7-CD27-) T cells in the CD4+ and CD8+ subpopulations.

[0293] result

[0294] Non-viral editing generated undifferentiated T cell products (Figure 46). Since the major T cell subsets in both donors and both subpopulations retained positive expression of CD45RA and CCR7, non-viral editing did not contribute to the expansion of terminally differentiated T cells (Figure 46). This suggests that edited T cells possess the ability to expand, survive, and persist in vivo.

[0295] References Eyquem, J., Mansilla-Soto, J., Giavridis, T., van der Stegen, SJ, Hamieh, M., Cunanan, KM,...&Sadelain, M. (2017). Targeting a CAR to the TRAC locus with CRISPR / Cas9 enhances tumour rejection. Nature, 543(7643), 113-117.

[0296] Sadelain,M.,Papapetrou,E.P.,&Bushman,F.D.(2012).Safe harbours for the integration of new DNA in the human genome.Nature reviews Cancer,12(1),51-58.

[0297] Irion,S.,Luche,H.,Gadue,P.,Fehling,H.J.,Kennedy,M.,&Keller,G.(2007).Identification and targeting of the ROSA26 locus in human embryonic stem cells.Nature biotechnology,25(12),1477-1482.

[0298] Pellenz,S.,Phelps,M.,Tang,W.,Hovde,B.T.,Sinit,R.B.,Fu,W.,...&Monnat Jr,R.J.(2019).New human chromosomal sites with“safe harbor”potential for targeted transgene insertion.Human gene therapy,30(7),814-828.

[0299] Roth,T.L.,Li,P.J.,Nies,J.F.,Yu,R.,Nguyen,M.L.,Lee,Y.,...&Nguyen,D.N.(2019).Rapid discovery of synthetic DNA sequences to rewrite endogenous T cell circuits.bioRxiv,604561. TIFF2023547887000005.tif202165TIFF2023547887000006.tif197165TIFF2023547887000007.tif197165TIFF2023547887000008.tif197165TIFF2023547887000009.tif189165TIFF2023547887000010.tif182165TIFF2023547887000011.tif172165TIFF2023547887000012.tif190165 TIFF2023547887000013.tif117160TIFF2023547887000014.tif238160TIFF2023547887000015.tif238160TIFF2023547887000016.tif238160TIFF2023547887000017.tif238160TIFF2023547887000018.tif238160TIFF2023547887000019.tif238160TIFF2023547887000020.tif238160TIFF2023547887000021.tif238160TIFF2023547887000022.tif238160TIFF2023547887000023.tif238160TIFF2023547887000024.tif238160TIFF2023547887000025.tif238160TIFF2023547887000026.tif238160TIFF2023547887000027.tif238160TIFF2023547887000028.tif238160TIFF2023547887000029.tif238160TIFF2023547887000030.tif238160TIFF2023547887000031.tif238160TIFF2023547887000032.tif238160TIFF2023547887000033.tif238160TIFF2023547887000034.tif238160TIFF2023547887000035.tif238160TIFF2023547887000036.tif238160TIFF2023547887000037.tif238160TIFF2023547887000038.tif238160TIFF2023547887000039.tif238160TIFF2023547887000040.tif238160TIFF2023547887000041.tif238160TIFF2023547887000042.tif238160TIFF2023547887000043.tif238160TIFF2023547887000044.tif238160TIFF2023547887000045.tif238160TIFF2023547887000046.tif238160TIFF2023547887000047.tif238160TIFF2023547887000048.tif238160TIFF2023547887000049.tif238160TIFF2023547887000050.tif238160TIFF2023547887000051.tif234160TIFF2023547887000052.tif238160TIFF2023547887000053.tif238160TIFF2023547887000054.tif238160TIFF2023547887000055.tif238160TIFF2023547887000056.tif238160TIFF2023547887000057.tif238160TIFF2023547887000058.tif238160TIFF2023547887000059.tif238160TIFF2023547887000060.tif238160TIFF2023547887000061.tif238160TIFF2023547887000062.tif238160TIFF2023547887000063.tif238160TIFF2023547887000064.tif238160TIFF2023547887000065.tif238160TIFF2023547887000066.tif238160TIFF2023547887000067.tif234160TIFF2023547887000068.tif238160TIFF2023547887000069.tif238160TIFF2023547887000070.tif234160TIFF2023547887000071.tif238160TIFF2023547887000072.tif238160TIFF2023547887000073.tif238160TIFF2023547887000074.tif238160TIFF2023547887000075.tif238160TIFF2023547887000076.tif238160TIFF2023547887000077.tif238160TIFF2023547887000078.tif238160TIFF2023547887000079.tif238160TIFF2023547887000080.tif238160TIFF2023547887000081.tif238160TIFF2023547887000082.tif238160TIFF2023547887000083.tif238160TIFF2023547887000084.tif238160TIFF2023547887000085.tif238160TIFF2023547887000086.tif238160TIFF2023547887000087.tif234160TIFF2023547887000088.tif238160TIFF2023547887000089.tif238160TIFF2023547887000090.tif234160TIFF2023547887000091.tif238160TIFF2023547887000092.tif238160TIFF2023547887000093.tif238160TIFF2023547887000094.tif238160TIFF2023547887000095.tif238160TIFF2023547887000096.tif238160TIFF2023547887000097.tif238160TIFF2023547887000098.tif238160TIFF2023547887000099.tif238160TIFF2023547887000100.tif238160TIFF2023547887000101.tif238160TIFF2023547887000102.tif238160TIFF2023547887000103.tif238160TIFF2023547887000104.tif234160TIFF2023547887000105.tif238160TIFF2023547887000106.tif238160TIFF2023547887000107.tif238160TIFF2023547887000108.tif238160TIFF2023547887000109.tif238160TIFF2023547887000110.tif238160TIFF2023547887000111.tif238160TIFF2023547887000112.tif238160TIFF2023547887000113.tif238160TIFF2023547887000114.tif238160TIFF2023547887000115.tif238160TIFF2023547887000116.tif238160TIFF2023547887000117.tif238160TIFF2023547887000118.tif238160TIFF2023547887000119.tif238160TIFF2023547887000120.tif238160TIFF2023547887000121.tif238160TIFF2023547887000122.tif238160TIFF2023547887000123.tif238160TIFF2023547887000124.tif238160TIFF2023547887000125.tif238160TIFF2023547887000126.tif238160TIFF2023547887000127.tif238160TIFF2023547887000128.tif238160TIFF2023547887000129.tif238160TIFF2023547887000130.tif238160TIFF2023547887000131.tif238160TIFF2023547887000132.tif234160TIFF2023547887000133.tif238160TIFF2023547887000134.tif238160TIFF2023547887000135.tif238160TIFF2023547887000136.tif177160.

Claims

1. 1. An engineered cell comprising at least one sequence encoding a transgene, said at least one sequence being inserted within a safe harbor locus, said safe harbor locus being any of the following: chr11: 128340000-128350000, chr10: 33130000-33140000, chr10: 72290000-72300000, chr11: 65425000-65427000 (NEAT1), chr15: 92830000-92840000, chr16: 11220000-11230000, chr2: 87460000-87470000, chr3: 186510000 14, wherein the engineered cell is at any one or more of the target loci selected from: chr1: 59450000-59460000, chr2: 59450000-59460000, chr3: 127980000-128000000, chr4: 7970000-7980000, APRT, B2M, CAPNS1, CBLB, CD2, CD3E, CD3G, CD5, EDF1, FTL, PTEN, PTPN2, PTPN6, PTPRC, PTPRCAP, RPS23, RTRAF, SERF2, SLC38A1, SMAD2, SOCS1, SRP14, SRSF9, SUB1, TET2, TIGIT, TRAC, and TRIM28.

2. The engineered cell described in claim 1, wherein at least one sequence encoding the introduced gene is operably linked to an endogenous promoter.

3. The engineered cell described in claim 1, wherein at least one sequence encoding the introduced gene is operably linked to an exogenous promoter.

4. The target locus is chr11: 128340000-128350000, chr10: 33130000-33140000, chr10: 72290000-72300000, chr11: 65425000-65427000 (NEAT1), chr15: 92830000-92840000, chr16: 1122000 2. The engineered cell of claim 1 , wherein the nucleotide sequence is selected from: 0-11230000, chr1: 87460000-87470000, chr3: 186510000-186520000, chr3: 59450000-59460000, chr8: 127980000-128000000, and chr9: 7970000-7980000.

5. 2. The engineered cell of claim 1, wherein the target locus is chr11:128340000-128350000, or chr15:92830000-92840000.

6. 2. The engineered cell of claim 1, wherein the target locus is a gene selected from APRT, B2M, CAPNS1, CBLB, CD2, CD3E, CD3G, CD5, EDF1, FTL, PTEN, PTPN2, PTPN6, PTPRC, PTPRCAP, RPS23, RTRAF, SERF2, SLC38A1, SMAD2, SOCS1, SRP14, SRSF9, SUB1, TET2, TIGIT, TRAC, and TRIM28.

7. 2. The engineered cell of claim 1, wherein the safe harbor locus is a GS94 integration site or a GS102 integration site of Table 4.

8. 4. The engineered cell of claim 3, wherein the exogenous promoter is an EF1a promoter.

9. 2. The engineered cell of claim 1, which is a stem cell, a natural killer (NK) cell, an induced pluripotent stem cell (iPSC), a human pluripotent stem cell (HSPC), a T cell, or a T cell precursor.

10. 2. The engineered cell of claim 1, wherein the transgene encodes a recombinant protein, a therapeutic agent, a chimeric antigen receptor (CAR), a prime receptor (primeR), and / or an RNAi molecule, optionally an shRNA, miRNA, or miR.

11. A composition comprising the engineered cells of any one of claims 1 to 10 and a pharmaceutical excipient.

12. 1. A guide ribonucleic acid (gRNA) for editing a cell at a safe harbor locus, the gRNA comprising any one of SEQ ID NOs: 94, 102, 1-93, 95-101, or 103-120.

13. 1. A method of editing a cell having chromosomal DNA, comprising inserting at least one sequence encoding a transgene into a safe harbor locus of the chromosomal DNA of the cell, the safe harbor locus being any of the following: chr11:128340000-128350000, chr10:33130000-33140000, chr10:72290000-72300000, chr11:65425000-65427000 (NEAT1), chr15:92830000-92840000, chr16:11220000-11230000, chr2:87460000-87470000, chr3:1 86510000-186520000, chr3: 59450000-59460000, chr8: 127980000-128000000, chr9: 7970000-7980000, APRT, B2M, CAPNS1, CBLB, CD2, CD3E, CD3G, CD5, EDF1, FTL, PTEN, PTPN2, PTPN6, PTPRC, PTPRCAP, RPS23, RTRAF, SERF2, SLC38A1, SMAD2, SOCS1, SRP14, SRSF9, SUB1, TET2, TIGIT, TRAC, and TRIM28.

14. The target locus is chr11: 128340000-128350000, chr10: 33130000-33140000, chr10: 72290000-72300000, chr11: 65425000-65427000 (NEAT1), chr15: 92830000-92840000, chr16: 11220 14. The method of claim 13, wherein the chromaticity is selected from chr1: 87460000-87470000, chr2: 186510000-186520000, chr3: 59450000-59460000, chr8: 127980000-128000000, and chr9: 7970000-7980000.

15. 14. The method of claim 13, wherein the target locus is chr11:128340000-128350000 or chr15:92830000-92840000.

16. 14. The method of claim 13, wherein the target locus is a gene selected from APRT, B2M, CAPNS1, CBLB, CD2, CD3E, CD3G, CD5, EDF1, FTL, PTEN, PTPN2, PTPN6, PTPRC, PTPRCAP, RPS23, RTRAF, SERF2, SLC38A1, SMAD2, SOCS1, SRP14, SRSF9, SUB1, TET2, TIGIT, TRAC, and TRIM28.

17. 14. The method of claim 13, wherein the transgene encodes a recombinant protein, a therapeutic agent, a chimeric antigen receptor (CAR), a prime receptor (primeR), and / or an RNAi molecule, optionally an shRNA, miRNA, or miR.

18. 14. The method of claim 13, wherein the at least one sequence comprises an exogenous promoter, the exogenous promoter being operably linked to the transgene.

19. The method of claim 13, wherein the cell is a T cell or a T cell precursor.

20. 14. The method of claim 13, wherein the at least one sequence is inserted using homology directed repair or homology-independent specific insertion.

21. 14. The method of claim 13, wherein the at least one sequence is inserted using one or more guide ribonucleic acid (gRNA) and one or more Cas9 endonucleases, wherein the one or more gRNAs comprise any one of SEQ ID NOs: 94, 102, 1-93, 95-101, or 103-120.

22. 1. An ex vivo method for obtaining an engineered cell or population thereof, comprising: a. obtaining cells; b. genetically modifying the cell by inserting at least one sequence encoding a transgene into a safe harbor locus, wherein the safe harbor locus is selected from the group consisting of chr11: 128340000-128350000, chr10: 33130000-33140000, chr10: 72290000-72300000, chr11: 65425000-65427000 (NEAT1), chr15: 92830000-92840000, chr16: 11220000-11230000, chr2: 87460000-87470000, chr3: 186510000 at any one or more of the target loci selected from: chr1: 59450000-59460000, chr2: 127980000-128000000, chr3: 59450000-59460000, chr4: 127980000-128000000, chr5: 7970000-7980000, APRT, B2M, CAPNS1, CBLB, CD2, CD3E, CD3G, CD5, EDF1, FTL, PTEN, PTPN2, PTPN6, PTPRC, PTPRCAP, RPS23, RTRAF, SERF2, SLC38A1, SMAD2, SOCS1, SRP14, SRSF9, SUB1, TET2, TIGIT, TRAC, and TRIM28; The ex vivo method comprising:

23. 23. The method of claim 22, wherein obtaining the cells comprises: (i) collecting a tissue sample from a subject; (ii) isolating the cells from the tissue sample; and (iii) culturing the cells in vitro.

24. 23. The method of claim 22, wherein the cell is a stem cell, a natural killer (NK) cell, an induced pluripotent stem cell (iPSC), a human pluripotent stem cell (HSPC), a T cell, or a T cell precursor.

25. 23. The method of claim 22, wherein the at least one sequence is inserted using homology directed repair or homology recombination independent specific insertion.

26. 23. The method of claim 22, wherein the genetic modification in step (b) comprises contacting the cell with one or more guide ribonucleic acid (gRNA), the at least one sequence, and one or more Cas9 endonucleases, wherein the one or more gRNAs and Cas9 endonucleases facilitate the insertion of the at least one sequence into chromosomal DNA within the safe harbor locus, and wherein the one or more gRNAs comprise any one of SEQ ID NOs: 94, 102, 1-93, 95-101, or 103-120.

27. 23. The method of claim 22, wherein the at least one sequence comprises an exogenous promoter, the exogenous promoter being operably linked to the transgene.

28. 11. A pharmaceutical composition for treating a subject having or at risk of having a disease, the pharmaceutical composition comprising an effective amount of an engineered cell according to any one of claims 1 to 10.

29. 28. A pharmaceutical composition for treating a subject having or at risk of having a disease, comprising an effective amount of a composition comprising the cells or population thereof obtained by the method of any one of claims 22 to 27.

30. 29. The pharmaceutical composition of claim 28, wherein the disease is cancer.